



Parameters associated with unsuccessful pessary fitting for pelvic organ prolapse up to three months follow-up: a systematic review and meta-analysis

Claudia Manzini^{1,2} · Lisan M. Morsinkhof³ · C. Huub van der Vaart¹ · Mariëlla I. J. Withagen¹ · Anique T. M. Grob⁴

Received: 8 February 2021 / Accepted: 5 April 2021 / Published online: 17 January 2022
© The Author(s) 2021

Abstract

Objectives To clarify which parameters are associated with unsuccessful pessary fitting for pelvic organ prolapse (POP) at up to 3 months follow-up.

Methods Embase, PubMed and Cochrane CENTRAL library were searched in May 2020. Inclusion criteria were: (1) pessary fitting attempted in women with symptomatic POP; (2) pessary fitting success among the study outcomes with a maximal follow-up of 3 months; (3) baseline parameters compared between successful and unsuccessful group. A meta-analysis was performed using the random effects model.

Main results Twenty-four studies were included in the meta-analysis. Parameters associated with unsuccessful pessary fitting were: age (OR 0.70, 95% CI 0.56–0.86); BMI (OR 1.35, 95% CI 1.08–1.70); menopause (OR 0.65 95% CI 0.47–0.88); de novo stress urinary incontinence (OR 5.59, 95% CI 2.24–13.99); prior surgery, i.e. hysterectomy (OR 1.88, 95% CI 1.48–2.40), POP surgery (OR 2.13, 95% CI 1.34–3.38), pelvic surgery (OR 1.81, 95% CI 1.01–3.26) and incontinence surgery (OR 1.87, 95% CI 1.08–3.25); Colorectal-Anal Distress Inventory-8 scores (OR 1.92, 95% CI 1.22–3.02); solitary predominant posterior compartment POP (OR 1.59, 95% CI 1.08–2.35); total vaginal length (OR 0.56, 95% CI 0.32–0.97); wide introitus (OR 4.85, 95% CI 1.60–14.68); levator ani avulsion (OR 2.47, 95% CI 1.35–4.53) and hiatal area on maximum Valsalva (OR 1.89, 95% CI 1.27–2.80).

Conclusion During counselling for pessary treatment a higher risk of failure due to the aforementioned parameters should be discussed and modifiable parameters should be addressed. More research is needed on the association between anatomical parameters and specific reasons for unsuccessful pessary fitting.

Keywords Pelvic organ prolapse · Vaginal pessaries · Pessary fitting · Predictive factors · Predictive parameters · Patients' characteristics

Abbreviations

BMI Body mass index
CRADI-8 Colorectal-Anal Distress Inventory-8

GH Genital hiatus
HRT Hormone replacement therapy
POP Pelvic organ prolapse
SUI Stress urinary incontinence
TPUS Transperineal ultrasound
TVL Total vaginal length

✉ Claudia Manzini

- ¹ Department of Obstetrics and Gynecology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
- ² Utrecht, The Netherlands
- ³ Magnetic Detection and Imaging, Faculty of Science and Technology, Technical Medical Centre, University of Twente, Enschede, The Netherlands
- ⁴ Multi-Modality Medical Imaging, Faculty of Science and Technology, Technical Medical Centre, University of Twente, Enschede, The Netherlands

Introduction

Vaginal pessaries are widely used as a conservative treatment option in the management of pelvic organ prolapse (POP) [1, 2] and have proven effective in relieving POP symptoms [3–5]. However, multiple attempts with different pessaries are sometimes required before obtaining an adequate fit [6]. Additionally, pessary fitting is reported as

unsuccessful in up to 59% of the women [7], the most common reasons being pessary dislodgment, discomfort/pain, de novo urinary symptoms and failure to relieve POP symptoms [8]. Many studies have been published on the factors associated with (un) successful pessary fitting for POP [7–39]. Among other potential predictors, age, body mass index (BMI), prior surgeries, predominant POP compartments and advanced POP have been assessed, but results differ across studies. It is thus necessary to clarify which parameters are associated with unsuccessful pessary fitting. This knowledge could improve the clinical practice of physicians dealing with POP: the counselling for pessary treatment would be more effective and more targeted, and potential parameters associated with failure would be known and discussed with the patient. In addition, modifiable factors could be addressed to increase the probability of success.

The aim of the current review and meta-analysis is to clarify which clinical, demographical and anatomical (assessed by clinical examination or imaging techniques) parameters are associated with unsuccessful pessary fitting for POP up to 3 months follow-up. A maximum of 3 months follow-up was chosen to focus on pessary fitting process instead of long-term pessary use.

Methods

Sources

The first author searched Emtree/MeSH terms and keywords related to prolapse, pessary and the exposures (i.e. parameters associated with unsuccessful pessary fitting) through Embase, PubMed and the Cochrane CENTRAL library. The outcome, e.g. unsuccessful pessary fitting, was not included in the search to avoid the risk of missing relevant records. The terms searched through Embase are reported in Table 1 (the same search strategy was translated to PubMed and Cochrane CENTRAL library). The final search was made on the 8 May 2020. No time restrictions were applied, while restrictions were used for language (i.e. English). All results were exported to RefWorks (Legacy version), and duplicates were removed. If an abstract and a paper reporting the same data were retrieved, the abstract was considered a duplicate and removed.

Eligibility criteria

Studies were included in which (1) pessary fitting was attempted in women with symptomatic POP (at least 80% of the study population had to have symptomatic POP), (2) one of the assessed outcomes was the success of “initial fitting” and/or “fitting process” with a maximal follow-up of 3 months (in the case of a longer follow-up, at least 80%

Table 1 Embase search strategy

Emtree terms	Prolapse	Pessary	Exposure(s)
	‘pelvic organ prolapse’	‘vagina pessary’	parameters
	‘pelvic floor prolapse’		‘prediction and forecasting’
			‘morphological trait’
			‘groups by age’
			‘body mass’
			‘body weight’
			‘gynecologic surgery’
Keywords	prolapse(s)	pessar*	predictor(s)
	cystocele		factor(s)
	‘anterior vaginal wall prolapse’		characteristic(s)
	‘anterior compartment prolapse’		parameter(s)
	‘uterus prolapse’		age
	‘uterine prolapse’		BMI
	‘descensus uteri’		weight
	‘vault prolapse’		surger(y,ies)
	‘apical prolapse’		hysterectom(y,ies)
	‘apical compartment prolapse’		compartment(s)
	rectocele		stage(s)
	enterocele		TVL
	‘posterior vaginal wall prolapse’		GH
	‘posterior compartment prolapse’		

BMI=body mass index; TVL=total vaginal length; GH=genital hiatus

of the unsuccessful group had to have discontinued the pessary within 3 months from the initial fitting) and (3) baseline parameters (i.e. clinical, demographic and anatomical parameters) were compared between the successful and unsuccessful group. Study design was not a selection criterion and studies reported only in conference abstracts were not excluded. In the following, “initial fitting” will refer to the first visit, which is considered successful if the patient leaves the clinic with a pessary that stays comfortably in place. “Fitting process” will refer to pessary use from initial fitting until a defined follow-up time. It is considered successful if the patient is still using the pessary at follow-up.

“Pessary fitting” will refer to both initial fitting and fitting process, if no distinction between the two is needed.

Study selection

To select records eligible for full text assessment, title and abstract were screened by the first and second author, independently from each other. Any disagreement was resolved by discussion and the opinion of a third party (last author). The full text of the selected records was independently assessed by the same two authors. Disagreements were again resolved by discussion and the opinion of a third party (last author). The authors of a record were contacted if the full text of their paper was not accessible either online or at our institutional library and if some relevant parts of the records were unclear [e.g. definition of pessary fitting (un)success, time to follow-up, statistical significance of the observed differences or incorrect numbers].

Data extraction

A standardized data extraction form was created to retrieve the information relevant to the research question. The following data were extracted: reference (first author, year, journal citation), study design type, study setting, inclusion and exclusion criteria, sample size, prolapse assessment (i.e. Pelvic Organ Prolapse Quantification system or Baden-Walker), pessary types used, assessment of initial fitting and/or fitting process, definition of successful fitting, success rate, time to follow-up, parameters compared between successful and unsuccessful group, significant parameters on univariate analysis and significant parameters on multivariate analysis (if performed). In case a record reported follow-ups beyond 3 months, only the parameters relating to the follow-ups of the first 3 months were extracted.

Assessment of risk of bias

The Newcastle-Ottawa Scale (NOS) for case-control studies was used to assess the risk of bias of the included full-text articles [40]. Records only available as abstracts (i.e. no full-text available) were not assessed because of the limited amount of information they can provide. The NOS is specifically designed for non-randomized studies. It consists of three domains: Selection, Comparability and Exposure. The maximum total score is nine (four for the Selection domain, two for the Comparability domain and three for the Exposure domain). The first item assessed in the Selection domain is the adequacy of case definition and requires an independent validation. Since the success of pessary fitting is mostly patient self-reported, and no independent validation is applicable, no points could be given to this item. Therefore, the maximum score for the Selection domain was 3. A standard

criterion for what constitutes a high-quality study base on the NOS has not yet been established. Generally, a study scoring ≥ 7 is considered high quality [41]. However, since no studies could get the maximum score on the Selection domain, we used a score of ≥ 6 as definition of high-quality studies.

Data synthesis

To produce a qualitative synthesis of the results, all parameters assessed on their association with unsuccessful pessary fitting were clustered in a limited number of domains. For each domain one table was produced enumerating all studies in which a specific parameter was assessed on univariate and/or multivariate analysis.

To assess pessary fitting success rate, the weighted success rate at different times to follow-up was calculated. Sub-analyses were made for those studies which excluded and included women with unsuccessful initial fitting.

A meta-analysis of the parameters compared between successful and unsuccessful group in at least two records was performed. All available studies were combined without making any distinction based on the time to follow-up. A study was not included in the meta-analysis if the necessary input data were not reported and if, after having contacted the authors, they did not provide the requested data. In case of overlap between study populations of two records, the record with the largest sample size reporting the parameter of interest was included in the analysis. The meta-analysis was done with the Comprehensive Meta-analysis (CMA) version 3 software. Input data for dichotomous variables were number of exposed (i.e. number of patients with a specific parameter, e.g. prior hysterectomy) and sample size of unsuccessful and successful group, when available, or odds ratio (OR) and confidence intervals. In the last case, unadjusted ORs were used in the meta-analysis. For continuous variable input data were mean, standard deviation (SD) and sample size of unsuccessful and successful group or, if a *t*-test was run to compare the two groups, *p* value and sample size of the two groups. If the data were reported as median and range (minimum-maximum) or interquartile range (IQR), the authors were contacted and asked for mean and SD. In case of no response, mean and SD would have to be imputed to include the study in the meta-analysis. At first, the meta-analysis was run excluding the studies that required data imputation. To test if the imputed data would have influenced the results, the meta-analysis was also run after data imputation. If the data were reported as median and range, the mean was imputed using the method described by Hozo et al. [42] and the SD was imputed using the method described by Wan et al. [43]. If the data were reported as median and IQR, mean and SD were derived using Wan's method. Authors were also contacted if they

reported a parameter as significant or not significant without providing quantitative data. A random effect model was applied for the analysis. The summary measure used was OR. Heterogeneity was assessed with Q test and I-squared. For the significant parameters the risk of publication bias was assessed with the trim and fill procedure [44]. The meta-analysis without data imputation is presented in the result section, while the meta-analysis with data imputation is reported in Appendix E.

The review was conducted in adherence to the PRISMA and MOOSE guidelines. The protocol of the review was not registered before implementation.

Results

Study selection

Using the search strategy described, 1084 unique records were identified. The screening of title and abstract left 151 records. Of these, 119 were excluded after full text assessment and are reported in Appendix A. Thirty-two records (27 papers and five conference abstracts) were included in the qualitative synthesis and 24 in the meta-analysis (Fig. 1).

Study characteristics

The characteristics of the 32 included records are enumerated in Table 2. In the following, the included records will be referred to according to the numbers reported in Table 2 and a superscript number will be used in the text. It has to be noted that there is an overlap between the study populations of Cheung et al. (2017) and Cheung et al. (2018) and Manchana (2011) and Manchana et al. (2012). In Appendix B the list of the authors contacted during the review process is reported.

Risk of bias

In Table 3 the Newcastle-Ottawa Scale scores for the three domains and the total scores are reported. Mean total score was 6.

Synthesis of results: success rate

Pessary fitting success rate ranged from 41%¹⁷ to 96%¹⁹. In Table 4 the weighted means at different times to follow-up are shown. Sub-analyses were made for those studies which excluded and included women with unsuccessful initial fitting. When the unsuccessful initial fitting was included, the

Fig. 1 Records identification, inclusions and exclusions with reasons




Table 2 Characteristics of the included records

Journal papers: authors, year	Journal	Inclusion criteria	Exclusion criteria	N*	Pessary types	Study design	Setting ²	Initial fitting/fitting process	Definition of success	Follow-up ³		Success rate fitting	
										Study	Review	Initial	Process
(1) Cheung et al. 2017	UOG	- Symptomatic POP - No prior POP treatment - Double-ring pessary allowed - Maximum 3 re-fittings	- POP surgery or pessary removal within 1st year - No documented 1-year follow-up	255	Ring (double allowed)	Prospective observational	A	Fitting process	No pessary expulsion within 1 year (96% expulsion within 2 weeks)	1 year	2 weeks	-	59
(2) Cheung et al. 2018	Maturitas	- Symptomatic POP - No prior POP treatment - Double-ring pessary allowed - Maximum 3 re-fittings	- POP surgery or pessary removal within 1st year - No documented 1-year follow-up	528	Ring (double allowed)	Prospective observational	A	Fitting process	No pessary dislodgement within 1st year (94% dislodgement within 2 weeks)	1 year	2 weeks	-	69
(3) Clemons et al. 2004	AJOG	Symptomatic POP stage ≥ 2	-	100	Ring with diaphragm, Gellhorn, donut, double pessary	Prospective observational	A	Both combined	Pessary use 1 week after initial fitting/ re-fitting (vs discontinuation within 2 weeks)	2 weeks		94	73
(4) Cundiff et al. 2007	AJOG	- Symptomatic POP stage ≥ 2 - Interest in non-surgical treatment	- Pregnancy - Prior pessary use - Vaginal narrowing or agglutination	134	Ring with support, Gellhorn	Randomized crossover trial	B	Both combined	Pessary use for 3 months	3 months		92	59 ^a
(5) Ding et al. 2015	IUJ	- Symptomatic POP stage 3–4 - Willingness to try a pessary	Unsuccessful initially fitting with a ring with support pessary	81	Ring with support	Prospective observational	C	Fitting process	Continued pessary use for > 3 months from the initial fitting	3 months		-	67

Table 2 (continued)

Journal papers: authors, year	Journal	Inclusion criteria	Exclusion criteria	N*	Pessary types	Study design	Set ting ^{#2}	Initial fitting/ fitting process	Definition of success	Follow-up ^{#3}		Success rate fitting	
										Study	Review	Initial	Process
(6) Fernando et al. 2006	Obstet Gynecol	- Symptomatic POP - Willingness to try a pessary	- Willingness to undergo surgery - Non-English speaking, learning difficulties, dementia	203	Ring, cube, Gellhorn, donut	Prospective observational	A	Both combined	Reduction of POP without discomfort at the 2-week follow-up	2 weeks	-	-	75
(7) Geoffrion et al. 2013	Female Pelvic Med Reconstr Surg	Symptomatic POP	-	101	Ring with/without support (with/without knob), Gellhorn, oval, donut, Gehrung	Retrospective	A	Both combined	Pessary use after 4 weeks from initial fitting	4 weeks	78	-	74
(8) Jones et al. 2008	Obstet Gynecol	- Symptomatic POP - Willingness to non-surgical treatment	- Current pessary use - Pessary contraindications (active infection vagina or pelvis, undiagnosed vaginal bleeding, erosions, severe dementia)	90	Ring with support, Gellhorn, incontinence ring with knob, oval pessary	Prospective, observational, cohort	A	Both combined	Successfully continued pessary use at the 3-month visit	3 months	-	-	47
(9) Ko et al. 2011	J Minim Invas Gyn	- Symptomatic POP stage ≥ 2 - Successful initial fitting with a Gellhorn	Gynecological malignancy	46	Gellhorn	Retrospective	A	Fitting process	Pessary use for > 2 months	1 year	2 months	-	80

Table 2 (continued)

Journal papers: authors, year	Journal	Inclusion criteria	Exclusion criteria	N*	Pessary types	Study design	Set-ting ^{#2}	Initial fit-ting/fitting pro-cess	Definition of success	Follow-up ^{#3}		Success rate fitting	
										Study	Review	Initial	Process
(10) Lekskulchai et al. 2015	J Med Assoc Thai	Women with POP treated with a pessary	Lost to follow-up before 3 months	194	Ring with/without support, donut, Gellhorn, pingpong ball	Retrospec-tive chart review	A	Fitting process	Pessary use for > 3 months	3 months	-	-	84
(11) Maito et al. 2006	J Midwifery Womens Health	- POP and/or urinary incontinence (87% POP or both) - Willingness to try a pessary	-	120	Most com-mon: ring with sup-port	Retrospec-tive chart review	E	Both com-bined	Comfort-able pessary retained on Valsalva and void at the time of fitting/re-fitting (maximum 3 times)	17 months	Initial visit/ refitting	90	86
(12) Man-chana, 2011	Arch Gynecol Obstet	- Symptomatic POP - Willingness to try a pessary	-	100	Ring	Retrospec-tive chart review	F	Both com-bined	Pessary use for > 2 weeks after initial fit-ting/re-fitting	13 months	2 weeks	77	62
(13) Manchana et al. 2012	IUJ	- Symptomatic POP - Willingness to try a pessary	-	126	Ring	Retrospec-tive chart review	F	Both com-bined	Pessary use for > 2 weeks after initial fit-ting/re-fitting	1 year	2 weeks	-	61
(14) Mao et al. 2018	BJOG	- Symptomatic POP (stage ≥ 2) - Willingness to try a pessary (i.e. mainly contraindica-tion/unwilling to undergo surgery, pos-sible future pregnancy or > 60 years old)	-	343	Ring with support/ Gellhorn	Prospective obser-vational	C	Both com-bined	Pessary use for > 2 weeks after initial fit-ting/re-fitting	2 weeks	-	92	88

Table 2 (continued)

Journal papers: authors, year	Journal	Inclusion criteria	Exclusion criteria	N*	Pessary types	Study design	Set ^{#2}	Initial fitting/fitting process	Definition of success	Follow-up ^{#3}		Success rate fitting	
										Study	Review	Initial	Process
(15) Markle et al. 2011	Female Pelvic Med Reconst Surg	Symptomatic POP without urinary incontinence	Missing data	158	Gellhorn, Shaatz, incontinence dish or ring, ring (with/without support), cube, donut, Gehrung, Inflatoball, Regula, Smith-Hodge	Retrospective observational	C	Both combined	Pessary comfortably retained and plan to continue its use at 1-week follow-up	1 week	-	-	59
(16) Mokrzycki et al. 2001	J Low Genit Tract Di	- Symptomatic POP - Willingness to try a pessary	- Suspicion of gynaecological malignancy - Unexplained vaginal bleeding - Prior pessary use	42	Ring with support, cube, Gellhorn, Smith-Hodge, donut	Retrospective chart review	A	Fitting process	Ability and desire to continue pessary use at 3-month follow-up	3 months	-	-	57
(17) Mutone et al. 2005	AJOG	- Symptomatic POP - Trial of pessary management	Lost to follow-up (n=23)	384	Ring with support, Gellhorn, cube, donut, Marland, Gehrung, Shaatz, Hodge, continence dish, regula, Inflatoball	Retrospective chart review	A	Both separate rate	1. Successful initial fitting 2. Patient still using the pessary at the 3 weeks follow-up and willing to continue	3 weeks	71	-	41

Table 2 (continued)

Journal papers: authors, year	Journal	Inclusion criteria	Exclusion criteria	N*	Pessary types	Study design	Setting ^{#2}	Initial fitting/ fitting process	Definition of success	Follow-up ^{#3}		Success rate fitting	
										Study	Review	Initial	Process
(18) Nemeth et al. 2013	IUJ	- Symptomatic POP stage ≥ 2 - Willingness to try a cube pessary as first-line treatment	- Undiagnosed vaginal bleeding - Vaginal erosions - Active vaginal infections - Dementia - Restricted mobility - Lost to follow-up (n=6)	78	Cube	Prospective cohort	A	Fitting process	Pessary use at 1-year follow-up (vs discontinuation 2–4 weeks after initial visit)	1 year	2–4 weeks	97	71
(19) Nemeth et al. 2017	IUJ	- Symptomatic POP stage ≥ 2 - Women intended to be treated with a vaginal pessary	- Active infections of the pelvis or vagina - Inability to remove and reinsert the pessary - Unlikely to follow up	629	Cube, ring with/ without support, ring with support and knob	Prospective cohort	A	Initial fitting	Successful initial fitting (vs failure to insert a pessary of appropriate size or loss/ displacement during Valsalva)	Initial visit		96	–
(20) Nguyen et al. 2005	J WOCN	- Pelvic floor relaxation - Preference for nonsurgical management	–	130	Ring (with/ without support), ring incontinent, Gellhorn, continence dish, Gehrung, cube, donut, regula	Retrospective chart review	C	Initial fitting	Successful initial fitting (vs inability to comfortably retain any pessary)	Initial visit		63	–

Table 2 (continued)

Journal papers: Journal authors, year	Inclusion criteria	Exclusion criteria	N*	Pessary types	Study design	Setting ^{#2}	Initial fitting/fitting process	Follow-up ^{#3}		Success rate fitting	
								Study	Review	Initial	Process
(21) Panman et al. 2017 IUJ	- Age ≥ 55 years - Symptomatic POP stage 2–3 - Women randomized to pessary (secondary analysis of a RCT)	- POP treatment in previous year - Current treatment for urogynecological disorders - Pelvic organ malignancy - Impaired mobility - Severe or terminal illness - Cognitive impairment - Insufficient Dutch language	78	Ring without/support, Shaatz, Gellhorn	Cross-sectional	G	Both combined	2 weeks	-	-	58
(22) Paterson et al. 2018 S Afr J Obstet Gynaecol	Symptomatic POP	- Allergic to silicone - Unwilling to undergo conservative treatment - Incomplete medical record (n = 6)	73	Ring with support	Retrospective cross-sectional	A	Both combined	1 year	1 month	-	-
(23) Ramsay et al. 2016 IUJ	- Symptomatic POP - ≥ 65 years, - Willingness to try a pessary	- Allergic to silicone - Unwilling to undergo conservative treatment - Incomplete medical record (n = 6)	304	Ring with support without/with knob, regula, donut, Shaatz, oval, Gehrung, Marland with support	Retrospective cohort	A	Both separate	12 years	1 month	-	63

Table 2 (continued)

Journal papers: authors, year	Journal	Inclusion criteria	Exclusion criteria	N*	Pessary types	Study design	Set ting*2	Initial fitting/ fitting process	Definition of success	Follow-up*3		Success rate fitting	
										Study	Review	Initial	Process
(24) Turel et al. 2020	Aust NZ J Obstet Gynaecol	- Symptomatic POP - Willingness to try a pessary	- Obvious pessary contraindication - Incomplete dataset - Lost to follow-up	84	Ring	Retrospective	A	Both combined	Pessary still in situ without complications at 3-month follow-up	3 months	-	50	-
(25) Wu et al. 1997	Obstet Gynaecol	- Symptomatic POP - Willingness to try a pessary	-	110	Ring with/ without support, cube	Prospective	C	Initial fitting	Successful initial fitting (i.e. pessary not expelled, patient could not feel the pessary, pessary did not descend to the introitus during testing)	4.5 years	Initial visit	74	-
(26) Yamada et al. 2011	J Obstet Gynaecol	- Uterine POP - Ring pessary treatment	-	69	Wallace ring pessary	Prospective	C	Fitting process	Pessary in situ for 4 weeks after the initial fitting (vs pessary expulsion)	1 month	-	-	77
(27) Yang et al. 2018	Arch Gynecol Obstet	Symptomatic POP	- Abnormal cervical cytology - Inflammation in the genital organs - Allergy to silicon	300	Ring with support, Gellhorn	Retrospective	F	Both combined	Retaining the pessary for 1 week without discomfort	8 years	1 week	-	83
Conference abstracts: authors, year	Journal	Inclusion criteria	Exclusion criteria	N*	Pessary types	Study design	Set ting*2	Initial fitting/ fitting process	Definition of success	Follow-up*3	Review	Initial	Process

Table 2 (continued)

Journal papers: authors, year	Journal	Inclusion criteria	Exclusion criteria	N*	Pessary types	Study design	Setting ^{#2}	Initial fitting/fitting process	Definition of success	Follow-up ^{#3}		Success rate fitting	
										Study	Review	Initial	Process
(A) Cho et al. 2015	Female Pelvic Med Reconst Surg	Pessary fitting for symptomatic POP	- Current pessary use without prior POPQ assessment - Pessary for SUI only - Prior pelvic radiation - Pregnant at pessary fitting - No documented 6-month follow-up	254	Support/ space occupying	Retrospective cohort	A	Fitting process	Pessary continuation \geq 4 weeks after initial fitting	4 weeks	-	-	65
(B) Hooper et al. 2018	Female Pelvic Med. Reconst. Surg.	- Symptomatic POP - Successful initial fitting with a cube pessary	-	25	Cube	Prospective observational	D	Fitting process	Ability to retain the pessary for up to 1 week	1 week	-	-	No report
(C) Umachanger et al. 2018	IUIJ	Symptomatic POP	-	130	Not specified	Retrospective chart review	C	Fitting process	Pessary use for > 3 months	3 months	-	-	67
(D) Triepels et al. 2019	Female Pelvic Med Reconst Surg.	- POP stage \geq 2 - Successful initial fitting	-	15	Not specified	Pilot	A	Fitting process	No pessary expulsion	< 3 months	-	-	-
(E) Zhu et al. 2011	IUIJ	- Symptomatic POP - ring pessary	-	66	Ring without support	Prospective	C	Fitting process	Satisfactory pessary fitting	1 month and 3 months	-	-	73 and 65

*N = number of patients included in the analysis

^{#2} Setting = A: tertiary centre, B: multicentre, C: gynaecology department, D: urology department, E: nurse-midwifery pessary clinic, F: gynaecology clinic, G: general practice^{#3} Follow-up: Study = longest time to follow-up assessed in the study; review = time to follow-up considered for the current review

x 59% = mean of the two trials of the randomized crossover trial

Abbreviations: POP = pelvic organ prolapse, SUI = stress urinary incontinence

Table 3 Newcastle-Ottawa Scale scores

Papers	Selection maximum 4	Com-parabil-ity maxi-mum 2	Exposure maximum 3	Total score maximum 9
Cheung et al. 2017	2	2	3	7
Cheung et al. 2018	2	2	3	7
Clemons et al. 2004	3	0	3	6
Cundiff et al. 2007	3	0	3	6
Ding et al. 2015	3	0	3	6
Fernando et al. 2006	3	2	3	8
Geoffrion et al. 2013	2	2	2	6
Jones et al. 2008	3	2	3	8
Ko et al. 2011	2	0	2	4
Lekskulchai et al. 2015	3	0	2	5
Maito et al. 2006	3	2	2	7
Manchana, 2011	3	0	1	4
Manchana et al. 2012	3	0	1	4
Mao et al. 2018	3	2	3	8
Markle et al. 2011	3	1	2	7
Mokrzycki et al. 2001	2	0	2	4
Mutone et al. 2005	3	0	2	5
Nemeth et al. 2013	3	0	3	6
Nemeth et al. 2017	3	2	3	8
Nguyen et al. 2005	3	1	2	6
Panman et al. 2017	3	2	3	8
Paterson et al. 2018	2	0	2	4
Ramsay et al. 2016	3	0	2	5
Wu et al. 1997	3	0	3	6
Yamada et al. 2011	3	0	3	6
Yang et al. 2018	3	0	2	5
Turel et al. 2020	3	2	2	7

success rates were overall lower (data at 3–4 weeks and 3 months). No sub-analysis was run for studies assessing

fitting process success rate at 1/2 weeks, because only one study excluded women with unsuccessful initial fitting².

Synthesis of results: parameters

The parameters assessed on their association with unsuccessful pessary fitting by different authors were clustered into nine domains: (1) Demographics, (2) Obstetric history, (3) (Uro) gynaecological symptoms and medications, (4) Prior surgeries, (5) General history, (6) Questionnaires, (7) POP and pelvic floor assessment, (8) Pessary and (9) Imaging. Appendix C shows the domain tables enumerating all studies in which a specific parameter was assessed on univariate and/or multivariate analysis. The results of the meta-analysis excluding imputed data are shown in Table 5 and the corresponding forest plots in Figs. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14 (significant parameters) and Appendix D (non-significant parameters).

Parameters associated with unsuccessful pessary fitting are: younger age, higher BMI, pre-menopausal status, stress urinary incontinence (SUI), prior surgery (i.e. hysterectomy, POP surgery, pelvic surgery, and incontinence surgery), higher Colorectal-Anal Distress Inventory-8 (CRADI-8) scores (which assess symptoms of obstructive defecation, anal incontinence, pain during defecation, faecal urgency and rectal bulging), shorter total vaginal length (TVL), wide introitus, levator ani avulsion and larger hiatal area on maximum Valsalva. The heterogeneity between studies and risk of publication bias is low for age, BMI, menopausal status, prior hysterectomy, prior pelvic surgery and prior incontinence surgery. SUI, prior POP surgery and TVL show a low risk of publication bias, but a relatively high heterogeneity between studies. For CRADI-8 scores, wide introitus, levator ani avulsion and hiatal area on Valsalva, the heterogeneity between studies is low, but the impact of publication bias could not be quantified because only two studies could be included in the analysis.

In Appendix E the results of the meta-analysis including imputed data are shown and in Appendix F the corresponding forest plots. Running the analysis without and with the imputed data did not qualitatively change the results: significant parameters remained significant and non-significant parameters remained non-significant. Sub-analyses were made for the parameters SUI and predominant posterior compartment. SUI is associated with unsuccessful pessary fitting (OR 2.06, 95% CI 1.15–3.66, z-value 2.45, *p* value 0.01). However, grouping the studies into those which assessed pre-existing SUI only and those which also assessed de novo SUI (alone or in combination with pre-existing SUI), de novo SUI remains significant (OR 5.59, 95% CI 2.24–13.99, z-value 3.68, *p* value 0.00), while pre-existing SUI does not (OR 1.44, 95% CI 0.88–2.36, z-value

Table 4 Weighted mean of pessary fitting success rate at different times to follow-up. Study reference refers to Table 2

Time to follow-up	Success rate: weighted mean		Study reference
Initial fitting	86% (95% CI 78%–92%)		3, 4, 7, 11, 12, 14, 17–20, 25
1–2 weeks	72% (95% CI 64%–79%)		2, 3, 6, 13–15, 21, 27
3–4 weeks	65% (95% CI 53%–76%)	Unsuccessful initial fitting excluded	70% (95% CI 62%–76%)
		Unsuccessful initial fitting included	60% (95% CI 40%–76%)
2 months	80% (95% CI 66%–89%)		9
3 months	63% (95% CI 53%–72%)	Unsuccessful initial fitting excluded	69% (95% CI 59%–78%)
		Unsuccessful initial fitting included	53% (95% CI 45%–66%)

1.45, p value 0.15) with small heterogeneity within groups (Q -value 11.17, p value 0.13).

Predominant posterior compartment is not associated with unsuccessful pessary fitting (OR 1.78, 95% CI 0.98–3.24, z -value 1.88, p value 0.06). However, in case of predominant multiple compartments (e.g. maximum POP stadium in the apical and posterior compartment), the patient was included in all relevant groups (e.g. predominant apical compartment POP and predominant posterior compartment POP). Analysing solitary predominant posterior compartment POP (i.e. excluding women with multiple predominant compartments), a significant association with unsuccessful fitting is observed (OR 1.59, 95% CI 1.08–2.35, z -value 2.37, p value 0.02, Q -value 4.51, df (Q) 5, Q -test p value 0.48, I -squared 0.00) with low risk of publication bias (trim and fill procedure: OR 1.75, 95% CI 1.21–2.53, Q -value 7.04).

Discussion

The aim of the current review and meta-analysis was to clarify which clinical, demographical and anatomical parameters are associated with unsuccessful pessary fitting for POP up to 3 months follow-up.

Main findings: success rate

In the current review the success rate of pessary fitting ranged from 41% to 96%. However, these differences become smaller if sub-analyses are made based on the follow-up time. From initial fitting to 3 to 4 weeks follow-up, the mean success rate decreased from 86% (95% CI 78%–92%) to 65% (95% CI 54%–75%). Interestingly, after 4 weeks the success rate remained substantially stable [success rate of 63% (95% CI 53%–72%) at 3 months follow-up]. This suggests that planning a follow-up at 4 weeks after initial fitting would ensure the vast majority of the unsuccessful fittings

were identified (as also reported by Lone et al. [45]). Studies in which only women with successful initial fitting were included reported higher success rates compared to studies in which also women with unsuccessful initial fitting were included. Therefore, our suggestion for future research is to clearly report whether this selection is made or not.

Main findings: parameters

Parameters associated with unsuccessful pessary fitting include: younger age, higher BMI, pre-menopausal status, SUI, prior surgery (i.e. hysterectomy, POP surgery, pelvic surgery and incontinence surgery), higher CRADI-8 scores, shorter TVL, wide introitus, levator ani avulsion and larger hiatal area on maximum Valsalva.

In the case of SUI and prior POP surgery, the risk of publication bias is small, but the heterogeneity is relatively high. With respect to SUI, analysing separately the studies which assessed pre-existing SUI only, and those which also assessed de novo SUI, the heterogeneity within groups becomes smaller. Interestingly, de novo SUI remains significant, while pre-existing SUI does not. This suggests that pre-existing SUI alone is not associated with failure. Therefore, when counselling a patient for pessary treatment for POP, presence of pre-existing SUI should not be considered a reason for advising a different treatment. With respect to prior POP surgery, a possible explanation for the relatively high heterogeneity is that all women of the unsuccessful group in the study of Nemeth et al. (2017) had prior POP surgery with consequent extremely high OR in this study compared to the others.

Some parameters that are significant in the meta-analysis have to be taken with caution. First, TVL shows high heterogeneity between studies. Second, the impact of publication bias could not be quantified for CRADI-8, wide introitus, levator ani avulsion and hiatal area on Valsalva because only two studies could be included in the analysis. In addition, levator avulsion shows moderate heterogeneity,

Table 5 Results of the meta-analysis (imputed data excluded)

Parameter	OR (95% CI)		z-value		p value		Heterogeneity		Trim and fill		Study number	
	OR	(95% CI)	z-value	p value	Q value	df (Q)	I-squared	OR (95% CI)	Q value			
Demographics												
Age	0.70	(0.56–0.86)	-3.31	0.00	20.14	14	0.13	30.49	0.70	(0.56–0.86)	20.14	2, 3, 4, 5, 7, 8, 13, 14, 15, 16, 19, 20, 24, 26, 27
BMI	1.35	(1.08–1.70)	2.63	0.01	8.30	7	0.31	15.70	1.31	(1.05–1.63)	9.49	2, 7, 13, 14, 15, 19, 24, 27
Menopause	0.65	(0.47–0.88)	-2.74	0.01	5.66	8	0.69	0.00	0.65	(0.47–0.88)	5.66	2, 7, 8, 9, 13, 15, 18, 20, 24
White ethnicity	0.96	(0.29–3.23)	-0.07	0.95	10.19	3	0.02	70.56	-	-	-	3, 4, 6, 7
Obstetric history												
No. pregnancies	0.71	(0.45–1.12)	-1.48	0.14	0.02	1	0.89	0.00	-	-	-	7, 27
No. deliveries	1.02	(0.62–1.67)	0.06	0.95	19.35	5	0.00	74.16	-	-	-	3, 6, 7, 19, 26, 27
No. vaginal deliveries	1.13	(0.73–1.74)	0.55	0.58	1.01	2	0.60	0.00	-	-	-	7, 15, 16
Largest baby ^o	1.65	(0.43–6.25)	0.73	0.46	6.99	2	0.03	71.39	-	-	-	5, 7, 14
(Uro) gynaecological symptoms and medications												
Stress urinary incontinence	2.06	(1.15–3.66)	2.45	0.01	22.33	8	0.00	64.18	1.88	(1.03–3.43)	26.28	3, 5, 7, 9, 13, 14, 16, 20, 14
Sexually active	1.27	(0.81–2.00)	1.04	0.30	9.46	5	0.09	47.17	-	-	-	2, 3, 7, 13, 15, 21
HRT	0.83	(0.51–1.35)	-0.75	0.45	9.25	5	0.10	45.94	-	-	-	3, 7, 8, 15, 20, 25
Prior surgeries												
Prior hysterectomy	1.88	(1.48–2.40)	5.09	0.00	17.99	15	0.26	16.63	1.88	(1.48–2.40)	17.99	2, 3, 6, 7, 8, 13, 14, 15, 17, 19, 20, 21, 24, 25, 26, 27
Prior POP surgery	2.13	(1.34–3.38)	3.21	0.00	27.30	10	0.00	63.37	2.13	(1.34–3.38)	27.30	3, 6, 7, 8, 14, 15, 17, 19, 20, 24, 25
Prior pelvic surgery	1.81	(1.01–3.26)	1.98	0.05	0.10	2	0.61	0.00	1.81	(1.01–3.26)	0.10	16, 21, 25
Incontinence surgery	1.87	(1.08–3.25)	2.24	0.03	1.01	3	0.80	0.00	1.87	(1.08–3.25)	1.01	7, 15, 20, 25
General history												
Smoking	1.65	(0.97–2.81)	1.85	0.64	3.16	4	0.53	0.00	-	-	-	5, 7, 20, 21, 24
Questionnaires												
CRADI-8	1.92	(1.22–3.02)	2.80	0.01	0.42	1	0.52	0.00	nm	nm	nm	7, 27
POP and pelvic floor assessment												
Predominant anterior compartment POP*	0.69	(0.40–1.19)	-1.34	0.19	24.21	7	0.00	71.09	-	-	-	2, 5, 8, 14, 16, 17, 21, 26
Predominant apical compartment POP*	1.31	(0.60–2.15)	0.38	0.71	16.14	5	0.01	69.02	-	-	-	2, 5, 8, 14, 17, 21
Predominant posterior compartment POP*	1.78	(0.98–3.24)	1.88	0.06	13.85	6	0.03	56.68	-	-	-	2, 8, 14, 16, 17, 21, 26
POPQ stadium 3–4	1.20	(0.62–2.31)	0.54	0.59	32.1	7	0.00	78.19	-	-	-	2, 3, 8, 9, 13, 14, 16, 17
TVL	0.56	(0.32–0.97)	-2.07	0.04	21.01	5	0.00	76.20	0.56	(0.32–0.97)	21.01	2, 5, 8, 10, 15, 24
GH	0.66	(1.25–2.39)	0.68	0.50	19.26	4	0.00	79.24	-	-	-	2, 5, 8, 15, 24
Perineal body	1.37	(0.83–2.28)	1.23	0.22	9.10	3	0.03	67.04	-	-	-	2, 8, 15, 24
Wide introitus**	4.85	(1.60–14.68)	2.80	0.01	0.45	1	0.50	0.00	nm	nm	nm	3, 12
GH/TVL	1.87	(0.86–4.05)	1.58	0.12	4.86	2	0.09	58.85	-	-	-	5, 7, 15

Table 5 (continued)

Parameter	OR (95% CI)	z-value	p value	Heterogeneity		Trim and fill		Study number
				Q value	df (Q)	I-squared	OR (95% CI)	
Pelvic floor strength	0.88 (0.50–1.54)	-0.45	0.65	0.22	1	0.00	-	7,24
Imaging								
Levator ani avulsion	2.47 (1.35–4.53)	2.93	0.00	1.56	1	36.00	nm	1, 24
Hiatal area Valsalva	1.89 (1.27–2.80)	3.18	0.00	0.98	1	0.00	nm	1, 24

Bold = statistically significant; †largest baby > 8 lbs (studies 5, 7) or 4 kg (study 14). *In case of predominant multiple compartments (e.g. maximum POP stadium in the anterior and apical compartment), the patient was included in all relevant groups (e.g. predominant anterior compartment POP and predominant apical compartment POP). **Wide introitus ≥ 4 fingerbreadths; nm = not measurable (to run a publication bias procedure at least three studies must be included); HRT = hormone replacement therapy; POP = pelvic organ prolapse; CRADI-8 = Colorectal-Anal Distress Inventory-8. The study number refers to Table 2

which can be explained by the different definitions of unsuccessful pessary fitting: pessary expulsion in the study of Cheung et al. and pessary discontinuation within 3 months follow-up in the study of Turel et al. The same explanation can be given to the moderate heterogeneity of other non-significant parameters, i.e. predominant apical compartment, advanced POP and GH. These parameters were associated with pessary dislodgment in the study of Cheung et al. but were not associated with unsuccessful pessary fitting when no distinction was made between different reasons for unsuccessful pessary fitting. The reasons for unsuccessful pessary fitting are numerous, e.g. dislodgment, discomfort/pain, de novo urinary symptoms and failure to relieve POP symptoms [8]. Some parameters could be associated only with specific reasons for pessary fitting failure, but not others; future research should analyse the association between anatomical parameters and individual causes of pessary fitting failure.

Parameters related to obstetric history, e.g. number of pregnancies, deliveries and vaginal deliveries, were not found to be associated with unsuccessful pessary fitting. However, no study assessed the influence of prior vaginal delivery vs no prior vaginal delivery on pessary fitting failure. If pessaries are supported by the pelvic floor muscles, prior vaginal delivery (which can cause pelvic floor muscles damage [46]) could be a risk factor for failure, even if POP mostly occurs in parous women. Being sexually active and hormone replacement therapy (HRT) use are not associated with (un) successful pessary fitting. Therefore, a sexually active woman with POP can be encouraged to try this treatment option and prescribing HRT only in case of indication is confirmed to be good practice.

Interestingly, advanced POP stage (3–4) is not associated with unsuccessful fitting. Therefore, pessary treatment can be advised to women with any stage of POP. Predominant anterior, apical or posterior compartment POPs are also not associated with unsuccessful fitting. However, higher CRADI-8 scores (which assess colorectal symptoms) and solitary predominant posterior compartment POP (i.e. maximum POP stage only in the posterior compartment, while women with multiple predominant compartments being excluded) are associated with unsuccessful fitting. These results confirm that pessary treatment is less effective in relieving colorectal symptoms [47].

Recently, a systematic review and meta-analysis has been published on the factors associated with unsuccessful pessary fitting in women with symptomatic POP [48]. Differences between their work and ours are the following. First, the follow-up for pessary fitting was 1 to 3 weeks in their work, while we included studies with a maximal follow-up of 3 months. Second, our search was performed

Fig. 2 Forest plots of the significant parameters (results of the meta-analysis excluding imputed data)




Fig. 3 Forest plot for the association of **age** with successful pessary fitting up to 3-month follow-up (N=2901)





Fig. 4 Forest plot for the association of **BMI** with unsuccessful pessary fitting up to 3-month follow-up (N=2244)



in Embase, PubMed and Cochrane CENTRAL library, while theirs was performed in PubMed, and we screened 1084 records, while they screened 350. Third, they only included prospective studies, while we also included retrospective studies. Fourth, we assessed the weighted success

rate of pessary fitting at different times to follow-up, which was not assessed in their work, while they assessed the reasons for pessary discontinuation after successful insertion, which we did not assess. Fifth, in our meta-analysis 24 studies were included, while 21 studies were

Fig. 5 Forest plot for the association of **menopausal status** with successful pessary fitting up to 3-month follow-up ($N=1338$)




Fig. 6 Forest plot for the association of **Stress urinary incontinence (SUI)** (i.e. pre-existing or de novo SUI) with unsuccessful pessary fitting up to 3-month follow-up ($N=1065$)





Fig. 7 Forest plot for the association of **prior hysterectomy** with unsuccessful pessary fitting up to 3-month follow-up ($N=3431$)



included in theirs. Sixth, we performed a meta-analysis of 29 parameters, while they performed a meta-analysis

of seven parameters. Seventh, we performed the analysis without and with data imputation, while they did not

Fig. 8 Forest plot for the association of **prior prolapse surgery** with unsuccessful pessary fitting up to 3-month follow-up ($N=2330$)




Fig. 9 Forest plot for the association of **prior pelvic surgery** with unsuccessful pessary fitting up to 3-month follow-up ($N=230$)




Fig. 10 Forest plot for the association of **prior incontinence surgery** with unsuccessful pessary fitting up to 3-month follow-up ($N=497$)




Fig. 11 Forest plot for the association of **“CRADI-8”** (i.e. Colorectal-Anal Distress Inventory-8) scores with unsuccessful pessary fitting up to 3-month follow-up ($N=401$)




Fig. 12 Forest plot for the association of **TVL** (i.e. total vaginal length) with successful pessary fitting up to 3-month follow-up ($N=1135$)




Fig. 13 Forest plot for the association of **wide introitus** (i.e. ≥ 4 fingerbreadths) with unsuccessful pessary fitting up to 3-month follow-up ($N=200$)





Fig. 14 Forest plot for the association of **levator ani muscle avulsion** with unsuccessful pessary fitting up to 3-month follow-up ($N=339$)



specify if imputed data were also included. With respect to the results, BMI and prior POP surgery were associated with pessary fitting failure in both works. In addition, GH was consistently not associated with pessary fitting failure. Different results were obtained for age, TVL, prior hysterectomy and advanced POP, which can be partially due to the differences described above. Furthermore, more studies were included in our meta-analysis, which should make our results more solid. Only three studies were included in the meta-analysis of the parameter “advanced POP” in their work. The one with the highest relative weight was the study of Cheung et al. in which the definition of failure was pessary dislodgment. It might be that advanced POP is a predictor of pessary dislodgment but not a predictor of other reasons for failure. Lastly, since we analysed more parameters, we also observed that menopausal status, de novo SUI, solitary predominant posterior compartment POP, higher CRADI-8 score, wide introitus, levator ani avulsion and larger hiatal area on maximum Valsalva are associated with unsuccessful pessary fitting.

Strengths and limitations

The current review and meta-analysis has several strengths. It was conducted according to the PRISMA and MOOSE guidelines. Multiple databases were searched. Study selection was made, independently, by two authors. The included papers were, on average, high-quality studies with a low risk of bias, as assessed by the Newcastle-Ottawa Scale. Moreover, authors were contacted in the case of missing information. Some limitations have to be acknowledged. Meta-analyses have the limitation

that the interaction between different parameters cannot be assessed. For example, it is highly probable that younger age and pre-menopausal status are correlated. However, we cannot establish whether one of the two is a confounder or both are independently associated with unsuccessful pessary fitting. In addition, mean and SD of continuous variables are needed to perform a meta-analysis, but some authors reported only median and range or median and IQR. To include these studies in the meta-analysis, mean and SD would have to be imputed. While we decided to exclude these studies from the meta-analysis to avoid any possible bias due to data imputation, we note that imputing mean and SD in these studies and including them do not qualitatively change the results: significant parameters remain significant and non-significant parameters remain non-significant. This suggests that our conclusions are robust.

Conclusions

In women with symptomatic POP, younger age, higher BMI, pre-menopausal status, de novo SUI, prior surgery (i.e. hysterectomy, POP surgery, pelvic surgery or incontinence surgery), solitary predominant posterior compartment POP, presence of colorectal symptoms, shorter TVL, wide introitus, levator ani avulsion and larger hiatal area on maximum Valsalva are associated with unsuccessful pessary fitting up to 3 months follow-up.

These results do not imply that an alternative treatment should always be recommended to women with these characteristics, but rather that the higher risk of failure should

be acknowledged and discussed during counselling for pessary treatment. Women with high risk of unsuccessful fitting because of, among others, a high BMI could work on this modifiable parameter to increase their probability of success, especially if they do not have many other treatment options (e.g. women who wish to have more children or those unwilling or not suitable to undergo surgery [49]). If pessary treatment is chosen, being aware of the higher risk of failure would relieve some of the frustration related to the unsuccessful pessary fitting process. One might object that such a counselling could lower women's expectation thus increasing the risk of failure. However, any counselling should be evidence based and should allow women to make informed decisions to be ethical. In addition, the risk of pessary fitting failure should be weighted against the risks related to other treatments (e.g. surgery), which in many cases would encourage women to try pessary treatment.

Ethnicity, obstetric history, pre-existing SUI, sexual activity, use of HRT, smoking, predominant anterior, apical or multiple compartment POP, and advanced POP are not associated with unsuccessful pessary fitting. Therefore, women with these characteristics can be reassured that they do not have an increased risk of failure and can be encouraged to try pessary treatment.

With respect to the anatomical parameters (assessed by clinical examination or imaging techniques), more research is needed to investigate their association with specific reasons for unsuccessful pessary fitting, i.e. whether it is dislodgment, discomfort/pain or other reasons. In addition, only two studies included in the meta-analysis assessed the association between TPUS parameters and unsuccessful pessary fitting. Therefore, the added value of TPUS in the pessary fitting process should be further investigated.

Appendix A List of the records excluded after full text assessment

- 1 Adams E, Thomson A, Maher C, Hagen S. Mechanical devices for pelvic organ prolapse in women. *Cochrane Database Syst Rev.* 2004;CD004010. <https://doi.org/10.1002/14651858.CD004010.pub2>.
- 2 Ai FF, Mao M, Zhang Y, Kang J, Zhu L. Effect of generalized anxiety disorders on the success of pessary treatment for pelvic organ prolapse. *Int Urogynecol J* 2018;29:1147–53. <https://doi.org/10.1007/s00192-018-3562-1>.
- 3 Ai F-F, Zhu L, Mao M, Zhang Y, Kang J. Depressive symptoms affect outcomes of pessary use in postmenopausal women with uterine prolapse. *Climacteric* 2018;21:184–8. <https://doi.org/10.1080/13697137.2018.1430130>.
- 4 Al-Badr A. Quality of life questionnaires for the assessment of pelvic organ prolapse: Use in clinical practice. *LUTS Low Urin Tract Symptoms* 2013;5:121–8. <https://doi.org/10.1111/luts.12006>.
- 5 Alnaif B, Drutz HP. The association of smoking with vaginal flora, urinary tract infection, pelvic floor prolapse, and post-void residual volumes. *J Low Genit Tract Dis* 2001;5:7–11. <https://doi.org/10.1046/j.1526-0976.2001.51002.x>.
- 6 Alperin M, Khan A, Dubina E, Tarnay C, Wu N, Pashos CL, et al. Patterns of pessary care and outcomes for medicare beneficiaries with pelvic organ prolapse. *Female Pelvic Med Reconstr Surg* 2013;19:142–7. <https://doi.org/10.1097/SPV.0b013e31827e857c>.
- 7 Anantawat T, Manonai J, Wattanayingcharoenchai R, Sarit-apirak S. Impact of a vaginal pessary on the quality of life in women with pelvic organ prolapse. *Asian Biomed* 2016;10:249–52. <https://doi.org/10.5372/1905-7415.1003.487>.
- 8 Armstrong K, Dessie S, Modest A, Hacker M, Hota L. The effect of vaginal oestrogen on pessary usage. *NeuroUrol Urodyn* 2014;18–21.
- 9 Atnip SD. Pessary use and management for pelvic organ prolapse. *Obstet Gynecol Clin North Am* 2009;36:541–63. <https://doi.org/10.1016/j.ogc.2009.08.010>.
- 10 Bai SW, Yoon BS, Kwon JY, Shin JS, Kim SK, Park KH. Survey of the characteristics and satisfaction degree of the patients using a pessary. *Int Urogynecol J Pelvic Floor Dysfunct* 2005;16:182–6; discussion 186. <https://doi.org/10.1007/s00192-004-1226-9>.
- 11 Bastani P, Solbian FE, Mokhtarkhani M, Yegani S, Kabiri N. Effects of vaginal pessaries on symptoms associated with pelvic organ prolapse. *Int.J.Urol.* 2014
- 12 Bastani P, Danandeh Osgui N. Improvement of concomitant symptoms of pelvic organ prolapsed with applied pessary. *Clin Exp Obstet Gynecol* 2019;46:42–4. <https://doi.org/10.12891/ceog4309.2019>.
- 13 Bezerra LS, Vasconcelos CT, Vasconcelos Neto J, Bezerra KD, Saboia DM, Oria MO, Do Nascimento TS, Reboucas RN, Viana VF. Adherence and follow-up to pessary using educational video: Prospective court. *Int Urogynecol J* 2017;28:S183–4.
- 14 Brincat C, Kenton K, Pat Fitzgerald M, Brubaker L. Sexual activity predicts continued pessary use. *Am J Obstet Gynecol* 2004;191:198–200. <https://doi.org/10.1016/j.ajog.2004.03.083>.

- 15 Broens-Oostveen MC, Mom RM, Lagro-Janssen ALM. [Genital prolapse; treatment and course in four general practices]. *Ned Tijdschr Geneesk* 2004;148:1444–8.
- 16 Bugge C, Adams EJ, Gopinath D, Reid F. Pessaries (mechanical devices) for pelvic organ prolapse in women. *Cochrane Database Syst Rev*. 2013;2013. <https://doi.org/10.1002/14651858.CD004010.pub3>.
- 17 Bulchandani S, Toozs-Hobson P, Verghese T, Latthe P. Does vaginal oestrogen treatment with support pessaries in vaginal prolapse reduce complications? *Post Reprod Heal* 2015;21:141–5. <https://doi.org/10.1177/2053369115614704>.
- 18 Chan MC, Hyakutake M, Yaskina M, Schulz JA. What Are the Clinical Factors That Are Predictive of Persistent Pessary Use at 12 Months? *J Obstet Gynaecol Can* 2019;41:1276–81. <https://doi.org/10.1016/j.jogc.2018.11.015>.
- 19 Cheung R, Chan S, Lee L. Factors associated with dislodgment of vaginal pessary within one year. *Int Urogynecol J Pelvic Floor Dysfunct* 2016;27:S132–3.
- 20 Cheung R, Lee L, Chan S. Does levator ani muscle injury affect the efficacy of vaginal pessary in women with pelvic organ prolapse. *Int Urogynecology J* 281 Suppl 1 (S96-S97) Date Publ 1 Jun 2017 2018:20–2.
- 21 Cheung RY-K, Lee L-L, Chung TK-H, Chan SS-C. Predictors for dislodgment of vaginal pessary within one year in women with pelvic organ prolapse. *Journal of Obstetrics and Gynaecology Research*. 2017
- 22 Cheung RYK, Lee JHS, Lee LL, Chung TKH, Chan SSC. Vaginal Pessary in Women With Symptomatic Pelvic Organ Prolapse: A Randomized Controlled Trial. *Obstet Gynecol* 2016;128:73–80. <https://doi.org/10.1097/AOG.0000000000001489>.
- 23 Chien C-W, Lo T-S, Tseng L-H, Lin Y-H, Hsieh W-C, Lee S-J. Long-term Outcomes of Self-Management Gellhorn Pessary for Symptomatic Pelvic Organ Prolapse. *Female Pelvic Med Reconstr Surg* 2019. <https://doi.org/10.1097/SPV.0000000000000770>.
- 24 Clemons JL, Aguilar VC, Sokol ER, Jackson ND, Myers DL. Patient characteristics that are associated with continued pessary use versus surgery after 1 year. *Am J Obstet Gynecol* 2004;191:159–64. <https://doi.org/10.1016/j.ajog.2004.04.048>.
- 25 Coelho SCA, Marangoni-Junior M, Brito LGO, Castro EB de, Juliato CRT. Quality of life and vaginal symptoms of postmenopausal women using pessary for pelvic organ prolapse: a prospective study. *Rev. Assoc Med Bras* 2018;64:1103–7. <https://doi.org/10.1590/1806-9282.64.12.1103>.
- 26 Daneel L, te West NI, Moore KH. Does monthly self-removal of vaginal ring pessaries for stress incontinence/prolapse reduce complication rates? A 5 year audit. *Neurourol Urodyn* 2016:5–8.
- 27 Davila GW. Vaginal prolapse: management with non-surgical techniques. *Postgrad Med* 1996;99:171–176,181,184–185.
- 28 Dekker JH, Burger H. Authors' reply to the comment by Hanis et al. on "Predictors of unsuccessful pessary fitting in women with prolapse: a cross-sectional study in general practice," by Panman et al. *Int Urogynecol J* 2017;28:1441. <https://doi.org/10.1007/s00192-017-3421-5>.
- 29 Deng M, Ding J, Ai F, Zhu L. Successful use of the Gellhorn pessary as a second-line pessary in women with advanced pelvic organ prolapse. *Menopause* 2017;24:1277–81. <https://doi.org/10.1097/GME.0000000000000909>.
- 30 Deng M, Ding J, Ai F, Zhu L. Clinical use of ring with support pessary for advanced pelvic organ prolapse and predictors of its short-term successful use. *Menopause* 2017;24:954–8. <https://doi.org/10.1097/GME.0000000000000859>.
- 31 Dengler EG, Mounsey LA, Gines F, Agha M, Long T, Geller EJ. Defecatory dysfunction and other clinical variables are predictors of pessary discontinuation. *Int Urogynecol J* 2019;30:1111–6. <https://doi.org/10.1007/s00192-018-3777-1>.
- 32 Dessie SG, Armstrong K, Modest AM, Hacker MR, Hota LS. Effect of vaginal oestrogen on pessary use. *Int Urogynecol J* 2016;27:1423–9. <https://doi.org/10.1007/s00192-016-3000-1>.
- 33 Ding J, Chen C, Song X-C, Zhang L, Deng M, Zhu L. Changes in Prolapse and Urinary Symptoms After Successful Fitting of a Ring Pessary With Support in Women With Advanced Pelvic Organ Prolapse: A Prospective Study. *Urology* 2016;87:70–5. <https://doi.org/10.1016/j.urology.2015.07.025>.
- 34 Ding J, Song X Chen, Deng M, Zhu L. Which factors should be considered in choosing pessary type and size for pelvic organ prolapse patients in a fitting trial? *Int Urogynecol J* 2016;27:1867–71. <https://doi.org/10.1007/s00192-016-3051-3>.
- 35 Duenas JL, Miceli A. Effectiveness of a continuous-use ring-shaped vaginal pessary without support for advanced pelvic organ prolapse in postmenopausal women. *Int Urogynecol J* 2018;29:1629–36. <https://doi.org/10.1007/s00192-018-3586-6>.
- 36 Dwyer L, Kearney R. Conservative management of pelvic organ prolapse. *Obstet Gynaecol Reprod Med* 2018;28:15–21. <https://doi.org/10.1016/j.ogrm.2017.10.005>.
- 37 Eberhard J, Geissbühler V. Pessary treatment in urogynaecology and obstetrics. *Gynakol Prax* 2002;26:119–33.
- 38 Espitia De La Hoz FJ. O-06 Evaluation of Quality of Life in Climacteric Women With Genital Prolapse after

- the Use of Pessary. *J Sex Med* 2017;14:e373–4. <https://doi.org/10.1016/j.jsxm.2017.10.016>.
- 39 Fitchett JR, Bhatta S, Sherpa TY, Malla BS, A Fitchett EJ, Samen A, et al. Non-surgical interventions for pelvic organ prolapse in rural Nepal: a prospective monitoring and evaluation study. *JRSM Open* 2015;6:2054270415608117. <https://doi.org/10.1177/2054270415608117>.
 - 40 Friedman S, Sandhu KS, Wang C, Mikhail MS, Banks E. Factors influencing long-term pessary use: Reply by the authors. *Int Urogynecol J* 2011;22:1047. <https://doi.org/10.1007/s00192-011-1393-4>.
 - 41 Friedman S, Sandhu KS, Wang C, Mikhail MS, Banks E. Factors influencing long-term pessary use. *Int Urogynecol J* 2010;21:673–8. <https://doi.org/10.1007/s00192-009-1080-x>.
 - 42 Fritzingler KG, Newman DK, Dinkin E. Use of a pessary for the management of pelvic organ prolapse. *Lippincotts Prim Care Pract* 1997;1:431–6.
 - 43 Geoffrion R, Zhang T, Lee T, Cundiff GW. Clinical characteristics associated with unsuccessful pessary fitting outcomes. *Obstet Gynecol Surv* 2014;69:79–81. <https://doi.org/10.1097/01.ogx.0000444678.89257.5f>.
 - 44 Goodman R.W.;Komesu Y.M.;McFadden B.L.;Rogers R.G. Do pessaries prevent prolapse progression? *Female Pelvic Med Reconstr Surg* 182 SUPPL 1 (S25-S26) 2015:4–6.
 - 45 Griebling TL. Re: Natural History of Pessary Use in Women Aged 65–74 versus 75 Years and Older with Pelvic Organ Prolapse: A 12-Year Study. *J Urol* 2017;197:1321. <https://doi.org/10.1016/j.juro.2017.02.041>.
 - 46 Griebling TL. Vaginal pessaries for treatment of pelvic organ prolapse in elderly women. *Curr Opin Urol* 2016;26:201–6. <https://doi.org/10.1097/MOU.000000000000266>.
 - 47 Griffin M, Kim Y, Roberts R, Abed H. Pessary use as a first line treatment for pelvic floor disorders. *Neurourol Urodynamics* 34 SUPPL 1 (S74) 2015;34:S2–98. <https://doi.org/10.1002/nau.22738>.
 - 48 Gupta P, Ehlert MJ, Bartley JM. Diagnosis and management of complex pelvic floor disorders in women. *J Clin Outcomes Manag* 2015;22:275–85.
 - 49 Gupta A, Cox X, Dunivan GC, Gaskins JT, Rogers RG, Iglesia CB, et al. Desire for Continued Pessary Use Among Women of Hispanic and Non-Hispanic Ethnic Backgrounds for Pelvic Floor Disorders. *Female Pelvic Med Reconstr Surg* 2020;26:287–98. <https://doi.org/10.1097/SPV>.
 - 50 Hagen S, Thakar R. Conservative management of pelvic organ prolapse. *Obstet Gynaecol Reprod Med* 2015;25:91–5. <https://doi.org/10.1016/j.ogrm.2015.01.006>.
 - 51 Handa VL, Jones M. Do pessaries prevent the progression of pelvic organ prolapse? *IUJ* 2002;13:349–52. <https://doi.org/10.1007/s0019202000078>.
 - 52 Hanis SM, Khazaei S, Ayubi E, Mansori K. Comment on: Predictors of unsuccessful pessary fitting in women with prolapse: a cross-sectional study in general practice. *Int Urogynecol J* 2017;28:1439. <https://doi.org/10.1007/s00192-017-3359-7>.
 - 53 Hanson L-AM, Schulz JA, Flood CG, Cooley B, Tam F. Vaginal pessaries in managing women with pelvic organ prolapse and urinary incontinence: patient characteristics and factors contributing to success. *Int Urogynecol J Pelvic Floor Dysfunct* 2006;17:155–9. <https://doi.org/10.1007/s00192-005-1362-x>.
 - 54 Hassler A, Michael K. The pessary, a method for treating pelvic organ prolapse. *J Diagnostic Med Sonogr* 2005;21:12–6. <https://doi.org/10.1177/8756479304272678>.
 - 55 Hooper GL. Person-Centered Care for Patients with Pessaries. *Nurs Clin North Am* 2018;53:289–301. <https://doi.org/10.1016/j.cnur.2018.01.006>.
 - 56 Hsieh M-F, Tsai H-W, Liou W-S, Lo C-C, Lin Z-H, An Y-F, et al. Long-term compliance of vaginal pessaries: Does stress urinary incontinence matter? *Medicine (Baltimore)* 2019;98:e15063. <https://doi.org/10.1097/MD.0000000000015063>.
 - 57 Jacobson NS, Taney J, Overbey J, Hardart A, J.A. F. Pessary use for management of pelvic organ prolapse in a tertiary care center: A retrospective review. *Female Pelvic Med Reconstr Surg* 235 Suppl 1(S90-S91)2017:3–5. <https://doi.org/10.1097/SPV.0000000000000479>.
 - 58 Johannes O., Promberger R., Nmeth Z. Vaginal cube pessaries for genital prolapse. *Climacteric* 2014;17:48–108. <https://doi.org/10.3109/13697137.2014.893733>.
 - 59 Jones KA, Harmanli O. Pessary use in pelvic organ prolapse and urinary incontinence. *Rev. Obstet Gynecol* 2010;3:3–9.
 - 60 Komesu YM, Rogers RG, Rode MA, Craig EC, Gallegos KA, Montoya AR, et al. Pelvic floor symptom changes in pessary users. *Am J Obstet Gynecol* 2007;197:620.e1–620.e6. <https://doi.org/10.1016/j.ajog.2007.08.013>.
 - 61 Komesu YM, Rogers RG, Rode MA, Craig EC, Schrader RM, Gallegos KA, et al. Patient-selected goal attainment for pessary wearers: what is the clinical relevance? *Am J Obstet Gynecol* 2008;198:577.e1–5. <https://doi.org/10.1016/j.ajog.2007.12.033>.
 - 62 Krause H. Pessary use in pelvic organ prolapse. *BJOG Int J Obstet Gynaecol*. 2015
 - 63 Kuhn A, Bapst D, Stadlmayr W, Vits K, Mueller MD. Sexual and organ function in patients with symptomatic prolapse: are pessaries helpful? *Fertil Steril* 2009;91:1914–8. <https://doi.org/10.1016/j.fertnstert.2008.02.142>.

- 64 Lalani S, Izett ML, Welford K, Lyons A, Kupelian A, Vashisht A. Outcomes of nurse-led pessary clinic for pelvic organ prolapse. *Female Pelvic Med Reconstr Surg*. 2019
- 65 Lamers BHC, Broekman BMW, Milani AL. Pessary treatment for pelvic organ prolapse and health-related quality of life: A review. *Int Urogynecol J* 2011;22:637–44. <https://doi.org/10.1007/s00192-011-1390-7>.
- 66 Lee HSJ, Cheung YR, Chan SS. Efficacy and complications of vaginal ring pessary in pelvic organ prolapse. *Neurourol Urodyn* 2014;1–2.
- 67 Lewthwaite BJ, Staley D, Girouard L, Maslow K. Characteristics of women with continued use of vaginal pessaries. *Urol Nurs* 2013;33:171–6.
- 68 Lone F, Thakar R, Sultan AH. One-year prospective comparison of vaginal pessaries and surgery for pelvic organ prolapse using the validated ICIQ-VS and ICIQ-UI (SF) questionnaires. *Int Urogynecol J* 2015;26:1305–12. <https://doi.org/10.1007/s00192-015-2686-9>.
- 69 Lone F, Thakar R, Sultan AH, Karamalis G. A 5-year prospective study of vaginal pessary use for pelvic organ prolapse. *Int J Gynaecol Obstet* 2011;114:56–9. <https://doi.org/10.1016/j.ijgo.2011.02.006>.
- 70 Lowenstein L, Gamble T, Sanses TVD, van Raalte H, Carberry C, Jakus S, et al. Changes in sexual function after treatment for prolapse are related to the improvement in body image perception. *J Sex Med* 2010;7:1023–8. <https://doi.org/10.1111/j.1743-6109.2009.01586.x>.
- 71 Manonai J, Sarit-Apirak S, Udomsubpayakul U. Vaginal ring pessary use for pelvic organ prolapse: Continuation rates and predictors of continued use. *Menopause* 2019;26:665–9. <https://doi.org/10.1097/GME.0000000000001277>.
- 72 Mao M, Ai F, Kang J, Zhang Y, Liang S, Zhou Y, et al. Successful long-term use of Gellhorn pessary and the effect on symptoms and quality of life in women with symptomatic pelvic organ prolapse. *Menopause* 2019;26:145–51. <https://doi.org/10.1097/GME.0000000000001197>.
- 73 Mao M, Ai F, Zhang Y, Kang J, Liang S, Xu T, et al. Changes in the symptoms and quality of life of women with symptomatic pelvic organ prolapse fitted with a ring with support pessary. *Maturitas* 2018;117:51–6. <https://doi.org/10.1016/j.maturitas.2018.09.003>.
- 74 Mao M, Xu T, Kang J, Zhang Y, Ai F, Zhou Y, et al. Factors associated with long-term pessary use in women with symptomatic pelvic organ prolapse. *Climacteric* 2019;22:478–82. <https://doi.org/10.1080/13697137.2019.1582623>.
- 75 Matsubara S. Factors influencing long-term pessary use: comment. *Int Urogynecol J* 2011;22:1045; author reply 1046. <https://doi.org/10.1007/s00192-011-1394-3>.
- 76 Nojima S, Wang L, S; Y Iwadare J, Nokazi N, Kanaeda T, et al. Long-term use of the vaginal ring pessary for pelvic organ prolapse-over 2 years follow up. *Int Urogynecol J Pelvic Floor Dysfunct* 2009;20 Suppl 3:241–491. <https://doi.org/10.1007/s00192-009-0982-y>.
- 77 Onwude JL. Genital prolapse in women. *BMJ Clin Evid* 2007;2007.
- 78 Onwude JL. Genital prolapse in women. *BMJ Clin Evid* 2009;2009.
- 79 Onwude JL. Genital prolapse in women. *BMJ Clin Evid* 2012;2012.
- 80 Panman CMCR, Wiegersma M, Kollen BJ, Berger MY, Lisman-van Leeuwen Y, Vermeulen KM, et al. Effectiveness and cost-effectiveness of pessary treatment compared with pelvic floor muscle training in older women with pelvic organ prolapse: 2-year follow-up of a randomized controlled trial in primary care. *Menopause* 2016;23:1307–18. <https://doi.org/10.1097/GME.0000000000000706>.
- 81 Patel M, Mellen C, O’Sullivan DM, LaSala CA. Impact of pessary use on prolapse symptoms, quality of life, and body image. *Am J Obstet Gynecol* 2010;202:499.e1–4. <https://doi.org/10.1016/j.ajog.2010.01.019>.
- 82 Patel MS, Mellen C, O’Sullivan DM, Lasala CA. Pessary use and impact on quality of life and body image. *Female Pelvic Med Reconstr Surg* 2011;17:298–301. <https://doi.org/10.1097/SPV.0b013e31823a8186>.
- 83 Pezzella M., Iervolino SA., Passaretta A., Torella M., Colacurci N. Sexual function among women using a pessary for pelvic organ prolapse. *Neurourol Urodyn* 2017;36:S5–87. <https://doi.org/10.1002/nau.23302>.
- 84 Pizarro-Berdichevsky J, Pattillo A, Blumel B, Gonzalez S, Arellano M, Cuevas R, et al. Prospective comparative results: Of pessary use in patients with symptomatic pelvic organ prolapse in patients above or below 65 years of age. *Neurourol Urodyn* 2015;34:S2–98. <https://doi.org/10.1002/nau.22738>.
- 85 Pizarro-Berdichevsky J, Pattillo A, Blumel B, Gonzalez S, Arellano M, Cuevas R, et al. Pessary use in patients with symptomatic pelvic organ prolapse-12 month prospective study of factors predictive of subjective improvement. *Int Urogynecol J* 2016;27:19–149. <https://doi.org/10.1007/s00192-016-3042-4>.
- 86 Poma PA. Nonsurgical management of genital prolapse. A review and recommendations for clinical practice. *J Reprod Med* 2000;45:789–97.
- 87 Powers K, Lazarou G, Wang A, LaCombe J, Bensinger G, Greston WM, et al. Pessary use in advanced pelvic organ prolapse. *Int Urogynecol J Pelvic Floor Dysfunct* 2006;17:160–4. <https://doi.org/10.1007/s00192-005-1311-8>.
- 88 Radnia N, Hajhashemi M, Eftekhari T, Deldar M, Mohajeri T, Sohbati S, et al. Patient Satisfaction and

- Symptoms Improvement in Women Using a Vginal Pessary for The Treatment of Pelvic Organ Prolapse. *J Med Life* 2019;12:271–5. <https://doi.org/10.25122/jml-2019-0042>.
- 89 Ralph C, Pohlhammer S, Blumel B, Pizarro-Berdichevsky J. Pessary use for symptomatic pelvic organ prolapse (SYMP POP) in patients <=65 years: Feasibility retrospective study. *Neurourol Urodyn* 2014;33:162–266. <https://doi.org/10.1002/nau.22577>.
- 90 Ramsay S, Bouchard F, Tu LM. Pelvic Organ Prolapse and Pessary Use: Is It a Viable Long Term Treatment Option? *J Urol* 2012;187:1–3. <https://doi.org/10.1016/j.juro.2012.02.2310>.
- 91 Ramsay S, Bouchard F, Tu LM, Sherbrooke U De. Long term outcomes of pessary use in women with pelvic organ prolapse. *Neurourol Urodynamics* 2011;30.
- 92 Robert M, Govan AJ, Lohani U, Uprety A. Feasibility of using pessaries for treatment of pelvic organ prolapse in rural Nepal. *Int J Gynaecol Obstet* 2017;136:325–30. <https://doi.org/10.1002/ijgo.12061>.
- 93 Robert M, Schulz JA, Harvey M-A. Technical update on pessary use. *JOGC* 2013;35:664–74. [https://doi.org/10.1016/S1701-2163\(15\)30888-4](https://doi.org/10.1016/S1701-2163(15)30888-4).
- 94 Sarit-Apirak S, Manonai J. Vaginal pessary use for pelvic organ prolapse in thai women. *Female Pelvic MedReconstrSurg* 2014;20:151–368.
- 95 Sarma S, Ying T, Moore KH. Long-term vaginal ring pessary use: discontinuation rates and adverse events. *BJOG* 2009;116:1715–21. <https://doi.org/10.1111/j.1471-0528.2009.02380.x>.
- 96 Scarabelot K, Pereira F, Ghizzo L, Willing J, Virtuoso J. Use of pessary in the treatment of pelvic floor dysfunctions: A systematic review. *Physiother Q* 2018;26:1–8. <https://doi.org/10.5114/pq.2018.74704>.
- 97 Shayo BC, Masenga GG, Rasch V. Vaginal pessaries in the management of symptomatic pelvic organ prolapse in rural Kilimanjaro, Tanzania: a pre-post interventional study. *Int Urogynecol J* 2019;30:1313–21. <https://doi.org/10.1007/s00192-018-3748-6>.
- 98 Sitavarin S, Wattanayingcharoenchai R, Manonai J, Sarit-apirak S, Chittacharoen A. The characteristics and satisfaction of the patients using vaginal pessaries. *J Med Assoc Thai* 2009;92:744–7.
- 99 Srikrishna S, Cardozo L. How Best to Manage the Posterior Compartment. *Curr. Bladder Dysfunct.Rep.* 2013
- 100 Sulak PJ, Kuehl TJ, Shull BL. Vaginal pessaries and their use in pelvic relaxation. *J Reprod Med* 1993;38:919–23.
- 101 Takashima Y, Dancz C, Ozel B. Factors associated with pessary discontinuation: A retrospective review. *Neuro-urol Urodyn* 2016. <https://doi.org/10.1002/nau.22967>.
- 102 Tan GI, Balakrishnan S. Factors that predict the medium-term success of the use of pessaries for symptomatic pelvic organ prolapse. *IntUrogynecolJ* 2018;10:1–15.
- 103 Tasic L, Jurisic A, Jankovic S, Karadzov N. Vaginal pessary is the best option for some women. *Maturitas* 2017;100:182. <https://doi.org/10.1016/j.maturitas.2017.03.213>.
- 104 te West NID, Moore KH. Recent Developments in the Non-surgical Management of Pelvic Organ Prolapse. *Curr Obstet Gynecol Rep* 2014;3:172–9. <https://doi.org/10.1007/s13669-014-0087-6>.
- 105 Tso C, Lee W, Austin-Ketch T, Winkler H, Zitkus B. Nonsurgical Treatment Options for Women With Pelvic Organ Prolapse. *Nurs Womens Health* 2018;22:228–39. <https://doi.org/10.1016/j.nwh.2018.03.007>.
- 106 Urzua M, Alvarez J, Rondini C, M M. Pessary use in pelvic organ prolapse in women. *Int Urogynecol J* 2017;28:1–282. <https://doi.org/10.1007/s00192-017-3337-0>.
- 107 van Geelen JM, Dwyer PL. Where to for pelvic organ prolapse treatment after the FDA pronouncements? A systematic review of the recent literature. *Int Urogynecol J* 2013;24:707–18. <https://doi.org/10.1007/s00192-012-2025-3>.
- 108 Vanherpe P, Ghesquière S. Use of pessaries in the treatment of pelvic organ prolapse. *Tijdschr Geneeskd* 2015;71:596–603. <https://doi.org/10.2143/TVG.71.09.2001854>.
- 109 Williams KS, Wolff BJ, Lind LR, Winkler HA. Vaginal oestrogen reduces adverse events in patients with pelvic organ prolapse managed with a pessary. *Female Pelvic Med Reconstr Surg* 2015;21:S76–7.
- 110 Withayajakkhajorn P, Limbutara W, Gorsagun C. Pessary expulsion rate and risk factors for expulsion in women with pelvic organ prolapsed in southern Thailand. *Int Urogynecol J* 2018;15:2017–9.
- 111 Wlzlak E, Kociszewski J, Krzycka M, Pazdrak M, Wlzlak W, Kluz T, et al. Daily used cube pessaries in women with pelvic organprolapse: Fitting, influence on pelvic floor function. *Int Urogynecol J* 2017;28:1–282. <https://doi.org/10.1007/s00192-017-3337-0>.
- 112 Wlzlak E, Kociszewski J, Krzycka M, Wlzlak W, Dunicz A, Surkont G. Ultrasound evaluation of the influence of cube pessaries on female’s pelvic floor. *Neurourol Urodyn* 2018:2018–21.
- 113 Wolff BJ., Williams KS., Lind LR., Winkler HA., Shalom DF. Predictive factors for long-term pessary use and discontinuation: A retrospective cohort study. *Female Pelvic Med Reconstr Surg* 2001;21:55–6.
- 114 Wolff B, Williams K, Winkler A, Lind L, Shalom D. Pessary types and discontinuation rates in patients with advanced pelvic organ prolapse. *Int Urogynecol J* 2017;28:993–7. <https://doi.org/10.1007/s00192-016-3228-9>.

115 Yimphong T, Temtanakitpaisan T, Buppasiri P, Chongsomchai C, Kanchaiyaphum S. Discontinuation rate and adverse events after 1 year of vaginal pessary use in women with pelvic organ prolapse. *Int Urogynecol J* 2018;29:1123–8. <https://doi.org/10.1007/s00192-017-3445-x>.

116 Zhu L, Mao M. Factors Associated with Long-Term Pessary Use in Women with Symptomatic Pelvic Organ Prolapse. *J Minim Invasive Gynecol* 2019;26:S210–1. <https://doi.org/10.1016/j.jmig.2019.09.437>.

117 Zhu L., Mao M., Ai F. Changes of symptoms and quality of life in women with symptomatic pelvic organ prolapse fitted with ring with support pessary: A long-term study. *Int Urogynecol J* 2018;10:1–15.

118 Li B, Chen Q, Zhang J, Yu C, Zhang L, Chen L. A prospective study of pessary use for severe pelvic organ prolapse: 3-year follow-up outcomes. *Arch Gynecol Obstet* 2020;301:1213–8. <https://doi.org/10.1007/s00404-020-05526-1>.

119 Yoshimura K, Morotomi N, Fukuda K, Kubo T, Taniguchi H. Changes of intravaginal microbiota and inflammation after self-replacement ring pessary therapy compared to continuous ring pessary usage for pelvic organ prolapse. *J Obstet Gynaecol Res* 2020;46:931–8. <https://doi.org/10.1111/jog.14242>.

Appendix B List of the authors contacted during the review process

Phase	Authors	Reason contact	Response		Conclusion
Response	Triepels et al.	Unclear time to follow-up	Yes	< 3 months	Abstract included
	Yang et al.	Abstract on the same data reported in the paper?	Yes	Abstract on the same data reported in the paper	Abstract considered as a duplicate
	Eberhard et al.	Record not retrieved	No		Not included
	Poma	Record not retrieved	No		Not included
	Poma	Record not retrieved	No		Not included

Appendix C. Each table shows the parameters of one specific domain. For each parameter the studies in which it was assessed on univariate and/ or multivariate analysis are reported as well as whether it was significant or not

Appendix C1 Demographics domain

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
Age	Cheung et al. 2017 Cheung et al. 2018 Clemons et al. Cundiff et al. Ding et al. Fernando et al. Geoffrion et al. Jones et al. Ko et al. Lekskulchai et al. Manchana, 2011 Manchana et al. 2012 Mao et al. Markle et al. Mokrzycki et al. Mutone et al. Nemeth et al. 2013 Nemeth et al. 2017 Nguyen et al. Ramsay et al. Wu et al. Yamada et al. Yang et al. Turel et al. Cho et al.	Cundiff et al. Fernando et al. Geoffrion et al. Mao et al. Wu et al.	Fernando et al. Geoffrion et al. Maito et al. Mao et al. Panman et al.	Geoffrion et al. Panman et al.

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
BMI/weight	Cheung et al. 2017 Cheung et al. 2018 Ding et al. Geoffrion et al. Ko et al. Leksukulchai et al. Manchana et al. 2012 Mao et al. Markle et al. Mutone et al. Nemeth et al. 2013 Nemeth et al. 2017 Nguyen et al. Yang et al. Turel et al. Cho et al.	Mao et al. Mutone et al.	Cheung et al. 2018 Maito et al. Mao et al. Panman et al.	Mao et al. Panman et al.
Menopause	Cheung et al. 2017 Cheung et al. 2018 Geoffrion et al. Jones et al. Ko et al. Manchana et al. 2012 Mao et al. Markle et al. Mokrzycki et al. Nemeth et al. 2013 Nguyen et al. Yang et al. Turel et al. Cho et al.	Mao et al. Turel et al.	Mao et al. Turel et al.	Turel et al.

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
Ethnicity	Clemons et al. Cundiff et al. Fernando et al. Geoffrion et al. Cho et al.	Cundiff et al. Cho et al.	Fernando et al.	–

Appendix C2 Obstetric history domain

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
Gravidity	Ding et al. Geoffrion et al. Mao et al. Yang et al.	–	–	–

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
Parity/ n. vaginal deliveries	Cheung et al. 2017 Cheung et al. 2018 Clemons et al. Ding et al. Fernando et al. Geoffrion et al. Jones et al. Ko et al. Leksukulchai et al. Manchana, 2011 Manchana et al. 2012 Mao et al. Markle et al. Mokrzycki et al. Nemeth et al. 2013 Nemeth et al. 2017 Nguyen et al. Ramsay et al. Wu et al. Yamada et al. Yang et al. Turel et al. Cho et al.	Fernando et al. Nemeth et al. 2013 Nemeth et al. 2017 Yang et al.	Fernando et al. Maito et al. Nemeth et al. 2017	Fernando et al.
Largest baby	Cheung et al. 2018 Ding et al. Geoffrion et al. Mao et al.	Geoffrion et al.	Panman et al. Geoffrion et al.	–
Assisted vaginal delivery	Geoffrion et al.	–	–	–
Tear into rectum	Geoffrion et al.	–	–	–

Appendix C3 (Uro) gynaecological symptoms and medications domain

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis assessment	Significant multivariate analysis
Urinary symptoms	Clemons et al. Ding et al. Geoffrion et al. Manchana et al. 2012 Mao et al. Markle et al. Mokrzycki et al. Nguyen et al. Ramsay et al. Wu et al. Zhu et al.	Mokrzycki et al. Nguyen et al. Wu et al.	Maito et al. Nguyen et al.	Nguyen et al.
De novo urinary incontinence	Ding et al. Ko et al. Nguyen et al.	Ko et al. Nguyen et al.	–	–
Sexually active	Cheung et al. 2017 Cheung et al. 2018 Clemons et al. Geoffrion et al. Manchana et al. 2012 Markle et al. Ramsay et al. Cho et al.	Cho et al.	–	–
Age of onset/ duration symptoms	Mokrzycki et al. Yang et al.	–	–	–
Vaginal hormones	Geoffrion et al. Jones et al. Cho et al.	–	–	–

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis assessment	Significant multivariate analysis
Oral hormones	Clemons et al. Geoffrion et al. Jones et al. Markle et al. Nguyen et al. Wu et al.	–	–	–
Postvoidal residual	Geoffrion et al.	–	–	–
Vaginal atrophy	Clemons et al. Mokrzycki et al. Ramsay et al.	–	–	–
Anal incontinence	–	–	Maito et al.	–
Pelvic pressure/lower backache	Nemeth et al. 2013	–	–	–
Discomfort	Ramsay et al.	–	–	–
POP necessitating manual reduction	Ramsay et al.	–	–	–

Appendix C4 Prior surgeries domain

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
Hysterec-tomy	Cheung et al. 2017 Cheung et al. 2018 Clemons et al. Ding et al. Fernando et al. Jones et al. Geoffrion et al. Manchana, 2011 Manchana et al. 2012 Mao et al. Markle et al. Mutone et al. Nemeth et al. 2013 Nemeth et al. 2017 Nguyen et al. Ramsay et al. Wu et al. Yamada et al. Yang et al. Turel et al. Cho et al. Hooper et al. Umachanger et al.	Fernando et al. Markle et al. Mutone et al. 2013 Nemeth et al. 2017 Ramsay et al. Cho et al. Hooper et al. Umachanger et al	Fernando et al. Maito et al. Nemeth et al. 2017 Panman et al. Turel et al. Ramsay et al. Nemeth et al. Turel et al.	Fernando et al. Maito et al. Turel et al.
POP surgery	Clemons et al. Ding et al. Fernando et al. Jones et al. Geoffrion et al. Mao et al. Markle et al. Mutone et al. Nemeth et al. 2013 Nemeth et al. 2017 Nguyen et al. Ramsay et al. Wu et al. Turel et al. Cho et al. Hooper et al. Umachanger et al.	Fernando et al. Mao et al. Mutone et al. Nemeth et al. 2013 Nemeth et al. 2017 Nguyen et al. Ramsay et al. Cho et al.	Fernando et al. Maito et al. Mao et al. Nemeth et al. 2017 Nguyen et al. Panman et al.	Maito et al. Nemeth et al. 2017 Nguyen et al.

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
Pelvic surgery	Geoffrion et al. Mokrzycki et al. Wu et al. Zhu et al. Umachanger et al.	Umachanger et al. Wu et al.	Panman et al.	–
Incontinence surgery	Geoffrion et al. Markle et al. Nguyen et al. Wu et al.	–	Maito et al.	–

Appendix C5 General history domain

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis assessment	Significant multivariate analysis
Comorbidities	Ding et al. Ko et al. Manchana et al. 2012 Yang et al.	Ko et al.	Maito et al.	–
Poor surgical candidate	Clemons et al.	–	–	–
Smoking	Ding et al. Geoffrion et al. Nguyen et al. Turel et al.	Geoffrion et al.	Geoffrion et al.	Geoffrion et al.
Family support	Ding et al. Ko et al.	Ko et al.	–	–
Constipation	Ding et al. Ramsay et al.	–	Maito et al.	–
Desire of surgery at the 1st visit	Clemons et al.	–	–	–

Appendix C6 Questionnaires domain

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
PFDI-20	Jones et al. Geoffrion et al. Yang et al.	–	–	–
POPDI-6	Geoffrion et al. Yang et al.	–	–	–
UDI-6	Geoffrion et al. Yang et al.	–	–	–
CRADI-8	Geoffrion et al. Yang et al.	Yang et al.	–	–
PFIQ-7	Geoffrion et al. Yang et al.	–	–	–
POPIQ-7	Geoffrion et al. Yang et al.	–	–	–
UIQ-7	Geoffrion et al. Yang et al.	–	–	–
CRAIQ-7	Geoffrion et al. Yang et al.	–	–	–
PEQ	Geoffrion et al.	–	–	–

Appendix C7 POP and pelvic floor assessment domain

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
Compartment	Cheung et al. 2017 Cheung et al. 2018 Clemons et al. Ding et al. Fernando et al. Jones et al. Geoffrion et al. Lekskulchai et al. Mao et al. Markle et al. Mokrzycki et al. Mutone et al. Ramsay et al. Yamada et al. Turel et al. Zhu et al.	Cheung et al. 2017 Cheung et al. 2018 Lekskulchai et al. Mao et al. Mutone et al. Turel et al. Ramsay et al. Yamada et al.	Cheung et al. 2017 Cheung et al. 2018 Maito et al. Mao et al. Panman et al.	Cheung et al. 2018 Maito et al.

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
Stage	Cheung et al. 2017 Cheung et al. 2018 Clemons et al. Ding et al. Fernando et al. Jones et al. Geoffrion et al. Ko et al. Manchana, 2011 Manchana et al. 2012 Mao et al. Markle et al. Mokrzycki et al. Mutone et al. Nemeth et al. 2013 Nguyen et al. Ramsay et al. Yamada et al. Cho et al. Hooper et al. Zhu et al.	Cheung et al. 2017 Cheung et al. 2018 Yamada et al. Cho et al. Hooper et al.	Cheung et al. 2017 Cheung et al. 2018 Geoffrion et al. Maito et al. Panman et al.	Cheung et al. 2017 Cheung et al. 2018 Geoffrion et al.
TVL	Cheung et al. 2018 Clemons et al. Ding et al. Jones et al. Lekskulchai et al. Manchana, 2011 Mao et al. Markle et al. Mutone et al. Turel et al. Zhu et al.	Cheung et al. 2018 Clemons et al. Lekskulchai et al. Manchana 2011 Mao et al. Markle et al.	Cheung et al. 2018 Mao et al. Markle et al.	Mao et al.

Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
Introitus width	Clemons et al. Manchana, 2011 Mao et al. Zhu et al.	Clemons et al. Manchana, 2011	–	–
GH	Cheung et al. 2018 Clemons et al. Ding et al. Jones et al. Lekskulchai et al. Manchana, 2011 Mao et al. Markle et al. Mutone et al. Turel et al.	Cheung et al. 2018	Cheung et al. 2018	Cheung et al. 2018
Pb	Cheung et al. 2018 Jones et al. Lekskulchai et al. Markle et al. Mutone et al. Turel et al. Wu et al.	Turel et al. Jones et al.	Turel et al. Jones et al.	Jones et al.
GH+Pb	Turel et al.	Turel et al.	Turel et al.	Turel et al.
GH/TVL	Ding et al. Geoffrion et al. Markle et al.	Markle et al.	Geoffrion et al. Markle et al.	Geoffrion et al.
Pelvic floor strength	Geoffrion et al. Mutone et al. Turel et al.	–	Maito et al. Panman et al.	Panman et al.

TVL = total vaginal length; GH = genital hiatus; Pb = perineal body

Appendix C8 Pessary domain


Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
Type	Fernando et al. Jones et al. Mutone et al. Wu et al. Cho et al.	Mutone et al. Cho et al.	Fernando et al.	–
Size	Nemeth et al. 2013	–	–	–
Self-insertion	Ding et al. Ko et al.	–	–	–
Insertion ease	Nemeth et al. 2013	Nemeth et al. 2013	–	–

Appendix C9 Imaging domain


Parameter	Univariate analysis assessment	Significant univariate analysis	Multivariate analysis Assessment	Significant multivariate analysis
TPUS	Cheung et al. 2017 Paterson et al. Turel et al.	Cheung et al. 2017 Paterson et al. Turel et al.	Cheung et al. 2017 Turel et al.	Cheung et al. 2017
MRI	Triepels et al.	Triepels et al.	–	–

TPUS = transperineal ultrasound; MRI = magnetic resonance imaging


Appendix D Forest plots of the non-significant parameters (imputed data excluded)



Appendix D.1. Forest plot for the association of white ethnicity with the outcome of pessary fitting up to 3 months follow-up (N= 521)




Appendix D.2. Forest plot for the association of “number of pregnancies” (N= 401) with the outcome of pessary fitting up to 3 months follow-up




Appendix D.3. Forest plot for the association of number of deliveries (N= 1402) with the outcome of pessary fitting up to 3 months follow-up


Appendix D.4. Forest plot for the association of number of vaginal deliveries with the outcome of pessary fitting up to 3 months follow-up (N= 301)




Appendix D.5. Forest plot for the association of largest baby (i.e. > 8 lbs. in Ding et al. and Geoffrion et al.; > 4 kg in Mao et al.) with the outcome of pessary fitting up to 3 months follow-up (N= 507)




Appendix D.6. Forest plot for the association of sexually active with the outcome of pessary fitting up to 3 months follow-up (N= 1085)




Appendix D.7. Forest plot for the association of hormonal replacement therapy with the outcome of pessary fitting up to 3 months follow-up (N= 663)



Appendix D.8. Forest plot for the association of “smoking” with the outcome of pessary fitting up to 3 months follow-up (N= 470)




Appendix D.9. Forest plot for the association of predominant anterior compartment with the outcome of pessary fitting up to 3 months follow-up (N= 1615). In case of predominant multiple compartments (e.g. maximum POP stadium in the anterior and apical compartment), the patient was included in all relevant groups (e.g. predominant anterior compartment POP and predominant apical compartment POP)




Appendix D.10. Forest plot for the association of predominant apical compartment with the outcome of pessary fitting up to 3 months follow-up (N= 1504). In case of predominant multiple compartments (e.g.


maximum POP stadium in the anterior and apical compartment), the patient was included in all relevant groups (e.g. predominant anterior compartment POP and predominant apical compartment POP)




Appendix D.11. Forest plot for the association of “predominant posterior compartment” with the outcome of pessary fitting up to 3 months follow-up (N= 1534). In case of predominant multiple compartments (e.g. maximum POP stadium in the anterior and apical compartment), the patient was included in all relevant groups (e.g. predominant anterior compartment POP and predominant apical compartment POP)




Appendix D.12. Forest plot for the association of prolapse stage 3 or 4 with the outcome of pessary fitting up to 3 months follow-up (N = 1658)




Appendix D.13. Forest plot for the association of GH (i.e. genital hiatus) with the outcome of pessary fitting up to 3 months follow-up (N = 941)




Appendix D.14. Forest plot for the association of perineal body with the outcome of pessary fitting up to 3 months follow-up (N = 860). A = success, B = failure




Appendix D.15. Forest plot for the association of GH/TVL with the outcome of pessary fitting up to 3 months follow-up (N= 340)



Appendix D.16. Forest plot for the association of pelvic floor strength with the outcome of pessary fitting up to 3 months follow-up (N= 185)




Appendix E Results of the meta-analysis including imputed data (only parameters requiring data imputation are shown)




Parameter	OR (95% CI)	z-value	p value	Heterogeneity			Trim and fill		Studies included	
				I ² value	df (Q)	p value	I ² value	Q value		
Demographics										
Age	0.69 (0.58–0.82)	−4.22	0.00	24.26	19	0.19	21.70	0.71 (0.60–0.85)	28.35	2, 3, 4, 5, 6, 7, 8, 10°, 13, 14, 15, 16, 17°, 18°, 19, 20, 21°, 24, 26, 27
BMI	1.45 (1.21–1.75)	3.93	0.00	10.67	10	0.38	6.28	1.29 (1.07–1.56)	17.49	2, 5°, 7, 13, 14, 15, 17°, 19, 21°, 24, 27
Obstetric history										
No. pregnancies	0.80 (0.57–1.14)	−1.24	0.22	0.84	3	0.84	0.00	–	–	5°, 7, 14°, 26
No. deliveries	0.80 (0.59–1.08)	−1.43	0.15	46.62	14	0.00	69.97	–	–	2°, 3, 5°, 6, 7, 8°, 10°, 13°, 18°, 19, 20°, 21°, 24°, 26, 27
No. vaginal deliveries	0.90 (0.65–1.26)	−0.60	0.55	6.05	4	0.20	33.92	–	–	2°, 7, 14°, 15, 16
Largest baby	1.53 (0.81–2.88)	1.30	0.19	10.52	4	0.03	61.97	–	–	2, 5°, 7°, 14°, 21°
Questionnaires										
CRADI-8	2.04 (1.37–3.04)	3.49	0.00	0.73	2	0.69	0.00	2.04 (1.37–3.04)	0.73	7, 21°, 27
POP and pelvic floor assessment										
TVL	0.44 (0.25–0.78)	−2.79	0.01	75.99	10	0.00	86.84	0.47 (0.27–0.83)	77.81	2, 3°, 5, 8, 10, 12°, 14°, 15, 17°, 21°, 24
GH	0.51 (0.91–1.62)	−0.33	0.74	90.59	10	0.00	88.96	–	–	2, 3°, 5, 8, 10°, 12°, 14°, 15, 17°, 21°, 24
Perineal body	1.24 (0.91–1.69)	1.35	0.18	10.07	5	0.07	50.36	–	–	2, 8, 10°, 15, 17°, 24
Introitus width	2.71 (1.61–4.58)	3.73	0.00	1.82	2	0.40	0.00	2.29 (1.33–3.94)	4.42	3°, 12°, 14°
Pelvic floor strength	0.57 (0.29–1.13)	−1.62	0.11	11.04	3	0.01	72.83	–	–	7, 17°, 21°, 24

Bold = statistically significant. *In case of predominant multiple compartments (e.g. maximum POP stadium in the anterior and apical compartment), the patient was included in all relevant groups (e.g. predominant anterior compartment POP and predominant apical compartment POP). °Mean and SD imputed. °Only available as dichotomous variable; **nm** = not measurable (to run a publication bias procedure at least three studies must be included); **HRT** = hormone replacement therapy; **POP** = pelvic organ prolapse; **CRADI-8** = Colorectal-Anal Distress Inventory-8. The study number refers to Table 2


Appendix F1 Forest plots of the significant parameters including imputed data (only parameters requiring data imputation are shown)




Appendix F1.1 Forest plot for the association of age with successful pessary fitting up to 3 months follow-up (N=3838)




Appendix F1.2. Forest plot for the association of BMI (N=2787) with unsuccessful pessary fitting up to 3 months follow-up




Appendix F1.3. Forest plot for the association of CRADI-8 (i.e. Colorectal-Anal Distress Inventory-8) scores with unsuccessful pessary fitting up to 3 months follow-up (N= 478)



Appendix F1.4. Forest plot for the association of TVL (i.e. total vaginal length) with successful pessary fitting up to 3 months follow-up (N= 2139). A = success, B = failure




Appendix F1.5. Forest plot for the association of introitus width with unsuccessful pessary fitting up to 3 months follow-up (N= 543)




Appendix F2 Forest plots of the non-significant parameters including imputed data (only parameters requiring data imputation are shown)


Appendix F2.1. Forest plot for the association of number of pregnancies (*N* = 825) with the outcome of pessary fitting up to 3 months follow-up




Appendix F2.2. Forest plot for the association of number of deliveries with the outcome of pessary fitting up to 3 months follow-up (*N* = 2790)




Appendix F2.3. Forest plot for the association of number of vaginal deliveries with the outcome of pessary fitting up to 3 months follow-up (*N* = 1138)



Appendix F2.4. Forest plot for the association of largest baby with the outcome of pessary fitting up to 3 months follow-up (N= 997)



Appendix F2.5. Forest plot for the association of GH (i.e. genital hiatus) with the outcome of pessary fitting up to 3 months follow-up (N = 2140)



Appendix F2.6. Forest plot for the association of perineal body with the outcome of pessary fitting up to 3 months follow-up (N= 1438)

Appendix F2.7. Forest plot for the association of pelvic floor strength with the outcome of pessary fitting up to 3 months follow-up (N= 647)

Authors' contribution Claudia Manzini: Conceptualization, Record screening, Formal analysis, Writing - Original Draft, Review and Editing.
 Lisan M. Morsinkhof: Record screening, Writing - Review and Editing.
 C. Huub van der Vaart: Conceptualization, Writing - Review and Editing.
 Mariëlla I.J. Withagen: Writing - Review and Editing.
 Anique T.M. Grob: Conceptualization, Record screening, Writing - Review and Editing.

Funding The study was part of the Gynaecological Imaging using 3D UltraSound (GYNIUS) project with number 15301, which is financed by the Dutch Research Council (NWO). Philips and TOMTEC contributed to the project by providing an ultrasound machine and an analysis software, which were not used for the current paper. The funding sources had no involvement in the study design, analysis, interpretation of data, report writing or preparation of this publication.

Declarations

Conflict of interest Authors declare no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Gorti M, Hudelist G, Simons A. Evaluation of vaginal pessary management: a UK-based survey. *J Obs Gynaecol*. 2009;29:129–31. <https://doi.org/10.1080/01443610902719813>.
- Cundiff GW, Weidner AC, Visco AG, Bump RC, Addison WA. A survey of pessary use by members of the American Urogynecologic Society. *Obstet Gynecol*. 2000;95:931–5. [https://doi.org/10.1016/s0029-7844\(00\)00788-2](https://doi.org/10.1016/s0029-7844(00)00788-2).
- Clemons JL, Aguilar VC, Tillinghast TA, Jackson ND, Myers DL. Patient satisfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for pelvic organ prolapse. *Am J Obs Gynecol*. 2004;190:1025–9. <https://doi.org/10.1016/j.ajog.2003.10.711>.
- Ding J, Chen C, Song XC, Zhang L, Deng M, Zhu L. Changes in prolapse and urinary symptoms after successful fitting of a ring pessary with support in women with advanced pelvic organ prolapse: a prospective study. *Urology*. 2016;87:70–5. <https://doi.org/10.1016/j.urology.2015.07.025>.
- Bugge C, Adams EJ, Gopinath D, Reid F. Pessaries (mechanical devices) for pelvic organ prolapse in women. *Cochrane Database Syst Rev*. 2013. <https://doi.org/10.1002/14651858.CD004010.pub3>.
- Clemons JL. Vaginal pessary treatment of prolapse and incontinence. *UpToDate*, Post, TW (Ed), UpToDate, Waltham, MA, 2014 2020.
- Mutone MF, Terry C, Hale DS, Benson JT. Factors which influence the short-term success of pessary management of pelvic organ prolapse. *AJOG*. 2005;193:89–94. <https://doi.org/10.1016/j.ajog.2004.12.012>.
- Mao M, Ai F, Zhang Y, Kang J, Liang S, Xu T, et al. Predictors for unsuccessful pessary fitting in women with symptomatic pelvic organ prolapse: a prospective study. *BJOG*. 2018;125:1434–40. <https://doi.org/10.1111/1471-0528.15260>.
- Cheung RYK, Lee JHS, Lee LL, Chung TKH, Chan SSC. Levator ani muscle avulsion is a risk factor for expulsion within 1 year of vaginal pessary placed for pelvic organ prolapse. *Ultrasound Obstet Gynecol*. 2017;50:776–80. <https://doi.org/10.1002/uog.17407>.
- Cheung RYK, Lee LLL, Chung TKH, Chan SSC. Predictors for dislodgment of vaginal pessary within one year in women with pelvic organ prolapse. *Maturitas*. 2018;108:53–7. <https://doi.org/10.1016/j.maturitas.2017.11.008>.
- Clemons JL, Aguilar VC, Tillinghast TA, Jackson ND, Myers DL. Risk factors associated with an unsuccessful pessary fitting trial in women with pelvic organ prolapse. *Am J Obstet Gynecol*. 2004;190:345–50. <https://doi.org/10.1016/j.ajog.2003.08.034>.
- Cundiff GW, Amundsen CL, Bent AE, Coates KW, Schaffer JI, Strohbehn K, et al. The PESSRI study: symptom relief outcomes of a randomized crossover trial of the ring and Gellhorn pessaries. *Am J Obstet Gynecol* 2007;196:405.e1–8. <https://doi.org/10.1016/j.ajog.2007.02.018>.
- Ding J, Chen C, Song X-C, Zhang L, Deng M, Zhu L. Successful use of ring pessary with support for advanced pelvic organ prolapse. *Int Urogynecol J*. 2015;26:1517–23. <https://doi.org/10.1007/s00192-015-2738-1>.
- Fernando RJ, Thakar R, Sultan AH, Shah SM, Jones PW. Effect of vaginal pessaries on symptoms associated with pelvic organ prolapse. *Obstet Gynecol*. 2006;108:93–9. <https://doi.org/10.1097/01.AOG.0000222903.38684.cc>.
- Geoffrion R, Zhang T, Lee T, Cundiff GW. Clinical characteristics associated with unsuccessful pessary fitting outcomes. *Female Pelvic Med Reconstr Surg*. 2013;19:339–45. <https://doi.org/10.1097/SPV.0b013e3182a26174>.
- Ko PC, Lo TS, Tseng LH, Lin YH, Liang CC, Lee SJ. Use of a pessary in treatment of pelvic organ prolapse: quality of life, compliance, and failure at 1-year follow-up. *J Minim Invasive Gynecol*. 2011;18:68–74. <https://doi.org/10.1016/j.jmig.2010.09.006>.
- Leksukulchai O, Wanichsetakul P. Factors affecting successfulness of vaginal pessary use for the treatment of pelvic organ prolapse. *J Med Assoc Thai*. 2015;98(Suppl 3):S115–20.
- Maito JM, Quam ZA, Craig E, Danner KA, Rogers RG. Predictors of successful pessary fitting and continued use in a nurse-midwifery pessary clinic. *J Midwifery Womens Health*. 2006;51:78–84. <https://doi.org/10.1016/j.jmwh.2005.09.003>.
- Manchana T. Ring pessary for all pelvic organ prolapse. *Arch Gynecol Obs*. 2011;284:391–5. <https://doi.org/10.1007/s00404-010-1675-y>.
- Manchana T, Bunyavejchevin S. Impact on quality of life after ring pessary use for pelvic organ prolapse. *Int Urogynecol J*. 2012;23:873–7. <https://doi.org/10.1007/s00192-011-1634-6>.
- Markle D, Skoczylas L, Goldsmith C, Noblett K. Patient characteristics associated with a successful pessary fitting. *Female Pelvic Med Reconstr Surg*. 2011;17:249–52. <https://doi.org/10.1097/SPV.0b013e31822f00ae>.
- Mokrzycki ML, Hatangadi SB, Zaccardi JE, Cox S. Preexisting stress urinary incontinence: a predictor of discontinuation with pessary management. *J Low Genit Tract Dis*. 2001;5:204–7.
- Nemeth Z, Nagy S, Ott J. The cube pessary: an underestimated treatment option for pelvic organ prolapse? Subjective 1-year outcomes. *Int Urogynecol J*. 2013;24:1695–701. <https://doi.org/10.1007/s00192-013-2093-z>.
- Nemeth Z, Farkas N, Farkas B. Is hysterectomy or prior reconstructive surgery associated with unsuccessful initial trial of pessary fitting in women with symptomatic pelvic organ prolapse? *Int Urogynecol J*. 2017;28:757–61. <https://doi.org/10.1007/s00192-016-3184-4>.
- Nguyen JN, Jones CR. Pessary treatment of pelvic relaxation: factors affecting successful fitting and continued use. *J Wound, Ostomy, Cont Nurs Off Publ Wound, Ostomy Cont Nurses Soc*. 2005;32:253–5. <https://doi.org/10.1097/00152192-200507000-00010>.

26. Panman CMC, Wiegersma M, Kollen BJ, Burger H, Berger MY, Dekker JH. Predictors of unsuccessful pessary fitting in women with prolapse: a cross-sectional study in general practice. *Int Urogynecol J*. 2017;28:307–13. <https://doi.org/10.1007/s00192-016-3107-4>.
27. Paterson FS, Abdool Z. Is pelvic floor morphology a predictor of successful pessary retention? Original research and review of the literature. *S Afr J Obstet Gynaecol*. 2018;24. <https://doi.org/10.7196/sajog.1360>.
28. Ramsay S, Tu LM, Tannenbaum C. Natural history of pessary use in women aged 65–74 versus 75 years and older with pelvic organ prolapse: a 12-year study. *Int Urogynecol J*. 2016;27:1201–7. <https://doi.org/10.1007/s00192-016-2970-3>.
29. Wu V, Farrell SA, Baskett TF, Flowerdew G. A simplified protocol for pessary management. *Obstet Gynecol*. 1997;90:990–4. [https://doi.org/10.1016/s0029-7844\(97\)00481-x](https://doi.org/10.1016/s0029-7844(97)00481-x).
30. Yamada T, Matsubara S. Rectocele, but not cystocele, may predict unsuccessful pessary fitting. *J Obstet Gynaecol*. 2011;31:441–2. <https://doi.org/10.3109/01443615.2011.577253>.
31. Yang J, Han J, Zhu F, Wang Y. Ring and Gellhorn pessaries used in patients with pelvic organ prolapse: a retrospective study of 8 years. *Arch Gynecol Obstet*. 2018;298:623–9. <https://doi.org/10.1007/s00404-018-4844-z>.
32. Turel Fatakia F, Pixton S, Caudwell Hall J, Dietz HP. Predictors of successful ring pessary use in women with pelvic organ prolapse. *Aust New Zeal J Obstet Gynaecol*. 2020;1–6. <https://doi.org/10.1111/ajo.13152>.
33. Cho MMM. Use of pelvic organ prolapse quantification (POPQ) measurements to predict pessary type for successful fitting. *Female Pelvic Med Reconstr Surg*. 2015;21:S77.
34. Hooper G, Davis A, Stafford M. Cube pessary use and quality of life in women with pelvic organ prolapse. *Female Pelvic Med Reconstr Surg*. 2018;24:S99.
35. Umachanger J, Marcussen M, Bøgild H, Kjærgaard N, Glavind K. First-line treatment of pelvic organ prolapse. *IUJ*. 2018;29:S60.
36. Zhu L, Wang W, Lang J, Chen H, Li L. Prospective study of ring pessary treatment for women with pelvic organs prolapse. *Int Urogynecol J Pelvic Floor Dysfunct*. 2011;22:S1423.
37. Triepels CP, Notten KJ, Weemhoff M, Kruitwagen RF, van Kruijk SM, Futterer JJ. Comparison of anatomical structures in women with successful and unsuccessful pessary therapy for pelvic organ prolapse (POP) 2019.
38. Handa VL, Jones M. Do pessaries prevent the progression of pelvic organ prolapse? *Int Urogynecol J Pelvic Floor Dysfunct*. 2002;13:349–51; discussion 352. <https://doi.org/10.1007/s001920200078>.
39. Jones K, Yang L, Lowder JL, Meyn L, Ellison R, Zyczynski HM, et al. Effect of pessary use on genital hiatus measurements in women with pelvic organ prolapse. *Obstet Gynecol*. 2008;112:630–6. <https://doi.org/10.1097/AOG.0b013e318181879f>.
40. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013 n.d. https://doi.org/10.1207/s15551407vcq1302_4.
41. Islam MM, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen PA, et al. Benzodiazepine use and risk of dementia in the elderly population: a systematic review and Meta-analysis. *Neuroepidemiology*. 2017;47:181–91. <https://doi.org/10.1159/000454881>.
42. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol*. 2005;5:1–10. <https://doi.org/10.1186/1471-2288-5-13>.
43. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014;14:1–13. <https://doi.org/10.1186/1471-2288-14-135>.
44. Shi L, Lin L, Omboni S. The trim-and-fill method for publication bias: Practical guidelines and recommendations based on a large database of meta-analyses. *Med (United States)* 2019;98. <https://doi.org/10.1097/MD.0000000000015987>.
45. Lone F, Thakar R, Sultan AH, Karamalis G. A 5-year prospective study of vaginal pessary use for pelvic organ prolapse. *Int J Gynaecol Obstet*. 2011;114:56–9. <https://doi.org/10.1016/j.ijgo.2011.02.006>.
46. Kamisan Atan I, Lin S, Dietz HP, Herbison P, Wilson PD. It is the first birth that does the damage: a cross-sectional study 20 years after delivery. *Int Urogynecol J*. 2018;29:1637–43. <https://doi.org/10.1007/s00192-018-3616-4>.
47. Dengler EG, Mounsey LA, Gines F, Agha M, Long T, Geller EJ. Defecatory dysfunction and other clinical variables are predictors of pessary discontinuation. *Int Urogynecol J*. 2019;30:1111–6. <https://doi.org/10.1007/s00192-018-3777-1>.
48. de Albuquerque Coelho S, Brito L, de Araujo C, Juliato C. Factors associated with unsuccessful pessary fitting in women with symptomatic pelvic organ prolapse: systematic review and metanalysis. *Neurourol Urodyn* 2020:1–10. <https://doi.org/10.1002/nau.24458>.
49. Barber MD. Pelvic organ prolapse. *BMJ*. 2016;354:1–9. <https://doi.org/10.1136/bmj.i3853>.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.